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ABSTRACT 
THE USE OF CERIUM OXIDE AND CURCUMIN NANOPARTICLES 
AS THERAPEUTIC AGENTS FOR THE TREATMENT OF 
VENTRICULAR HYPERTROPHY FOLLOWING 
PULMONARY ARTERIAL HYPERTENSION 
 
 Pulmonary arterial hypertension (PAH) is a progressive and fatal disease 
characterized by inflammation, increased pulmonary vascular resistance, right 
ventricular failure and premature death. Monocrotaline (MCT) has been used to induce 
PAH in laboratory rats. Previous in vitro and in vivo work suggested that cerium oxide 
(CeO2)-and curcumin nanoparticles exhibit anti-inflammatory activity; however, it is 
unknown if these materials are effective for the treatment of PAH induced cardiac 
hypertrophy. 
 To determine the efficacy of CeO2 nanoparticle treatment in preventing MCT-
induced RV hypertrophy, male Sprague Dawley rats were divided into one of three 
groups (control, MCT, or MCT + CeO2 nanoparticle, n=6/group). MCT was administered 
at a dosage of 60mg/kg subcutaneously. CeO2 nanoparticle treated animals received 
0.1mg/kg via tail vein injection twice a week for two weeks. Echocardiography was 
performed before and at the completion of the study. CeO2 nanoparticles treatment 
attenuated MCT-induced increases in RV mass, cardiomyocyte cross sectional area, 
and diminished cardiac oxidative stress levels. These changes in cardiac structure and 
oxidative stress were accompanied by decreased mitogen activated protein kinase 
phosphorylation, diminished heat shock proteins expression, improvements in the 
Bax/Bcl-2 ratio, and diminished caspase-3 activation. 
xviii 
 
 To investigate the efficacy of curcumin nanoparticle (Cur NP) administration in 
preventing PAH-induced cardiac remodeling after pulmonary arterial hypertension, rats 
were divided into one of three groups (control, MCT, or MCT + Cur NP treatment, 
n=6/group). MCT was injected at a dosage of 60mg/kg subcutaneously. Nanoparticle 
treated animals received Cur NP (50mg/kg i.p.) for seven days. Cur NP treatment 
diminished MCT-induced increases in pulmonary arterial pressures, RV thickness and 
myocardial fibrosis. These changes in cardiac structure were accompanied by down 
regulation of myosin heavy chain (MCH-β) and fibronectin protein. Cur NP treatment 
also reduced expression of tissue tumor necrosis factor (TNF-α) and interleukin-1β (IL-
1β) mRNA levels, decreased heat shock protein expression and reduced the amount of 
protein nitrosylation. 
 Taken together, the results of these studies suggest that administration of 
CeO2/curcumin nanoparticles may attenuate the degree of cardiac remodeling typically 
observed following the development of pulmonary arterial hypertension in the laboratory 
rat. Additional studies to investigate the mechanism(s) underlying these changes may 
be warranted. (WC: 349) 
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CHAPTER I 
INTRODUCTION 
Pulmonary arterial hypertension (PAH) is an increase in mean pulmonary arterial 
pressure >25 mm Hg at rest, or >30 mm Hg during exertion. PAH is characterized by 
vascular proliferation and remodeling of the small pulmonary arteries, which results in a 
progressive increase in pulmonary vascular resistance. The increased resistance can 
cause pressure overload and lead to right ventricular (RV) hypertrophy, which if allowed 
to proceed unchecked can terminate in heart failure and death [1]. The prognosis of 
patients with PAH remains poor, with approximately 10%–15% mortality within 1 year of 
the diagnosis. The median life expectancy from the time of diagnosis in patients with 
idiopathic PAH without targeted treatments is 2.8 years, with 1-year, 3-year, and 5-year 
survival rates of 68%, 48%, and 34%, respectively [2].  As of yet, a cure for PAH has not 
yet been found. Limitations in evaluating treatment approaches for PAH include its 
rarity, the inclusion of small number of patients in clinical trials, and issues regarding the 
use of placebo controlled trials in a disease with high mortality if left untreated [3]. 
 
The current treatment options for PAH include prostacyclin and prostacyclin 
analogues (e.g., Epoprostenol, Treprostinil, Iloprost), Endothelin receptor antagonists 
(e.g., Bosentan, Ambrisentan) and phosphodiesterase (PDE-5) inhibitors (e.g., 
Sildenafil, Tadalafil, Vardenafil), as well as traditional background therapy with diuretics 
(e.g., Furosemide), calcium-channel blockers (e.g., Dilitiazem, Nifedipine) and 
anticoagulation agents (e.g., warfarin) [4]. Even with modern medical therapy, most 
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patients experience progression of their disease and many are referred for lung 
transplantation [5]. 
 
Increases in oxidative stress due to excessive levels of reactive oxygen species 
(ROS), e.g., superoxide anion (•O2
-), hydroxyl radical (•OH), and hydrogen peroxide 
(H2O2) have been implicated in the pulmonary and cardiac dysfunction [6]. It is well 
known that ROS may damage tissues either by direct oxidation of key biological 
molecules (i.e., lipid peroxidation, DNA damage) or by inducing the activation of 
transcription factors, e.g., nuclear factor-kB (NF-kB) leading to apoptosis [7]. Recent 
studies have shown that ROS may be produced in the lung tissue of patients with 
severe PAH as a consequence of tissue hypoxia or through the activation of 
inflammatory mediators [8]. Indeed, inflammation has been shown to play a significant 
role in PAH associated with connective tissue diseases and HIV infection through the 
activation of inflammatory cascades and increased production of inflammatory cytokines 
(TNF-α,IL-1β,IL-6) [9]. It is thought that excessive oxidative stress and increased tissue 
levels of inflammatory mediators can damage small pulmonary arterioles, which can 
result in an increase in pressure overload and right heart failure [10].  
 
Monocrotaline (MCT) is a toxic pyrrolizidine alkaloid present in the plant 
Crotalaria spectabilis that can cause injury to the vasculature of the lungs and 
pulmonary arterial hypertension in animals [11]. Lung injury following MCT exposure is 
thought to occur after MCT processing in the liver by cytochrome P450 
monooxygenases and the conversion of MCT to pyrrolic metabolites, which travel via 
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the circulation to the lung [12]. In Sprague Dawley rats a single dose of 60 mg/kg MCT 
induces a rapid intrapulmonary inflammatory response, which increases inflammatory 
monocytes in the adventitia of pulmonary resistance arterioles within 8-16 h after 
injection [13]. Muscularization of nonmuscular arterioles leading to increased medial 
layer thickness is detectable as early as 3 and 7 days post injection and reaches 
significance by 10 and 14 days, resulting in increased pulmonary vascular resistance 
and pulmonary arterial hypertension. RV hypertrophy is apparent by 21 days and 
becomes progressively more severe if left untreated [14]. Whether strategies designed 
to diminish ROS levels and inflammatory mediators are efficacious in improving MCT 
induced PAH and RV function are not well understood. 
 
Cerium is a rare earth element of the lanthanide series, having a fluorite lattice 
structure in which the unit cell, consisting of cerium atoms arranged face-centered with 
oxygen atoms, are located within the cell in the tetrahedral interstices. Most of the rare 
earth elements exist in trivalent state (+3), but the cerium atom can exist in either Ce+3 
(fully reduced) or +4 (fully oxidized) state [15]. Due to its redox capacity, cerium oxide 
(CeO2) is an excellent oxygen buffer causing simultaneous oxidation of hydrocarbons 
as well as the reduction of oxides of nitrogen, thus reducing the emissions from the 
diesel exhaust as fuel additive [16]. CeO2 can exhibit oxygen vacancies or defects in 
lattice structure through the loss of oxygen or its electrons. These defects in CeO2 
structure are dynamic and can be altered by changes in temperature, the presence of 
ions, or variations in the partial pressure of oxygen [17]. Recent work has demonstrated 
that decreases in CeO2 nanoparticle size is associated with the formation of oxygen 
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vacancies [18] and increased catalytic activity [19]. Recently, CeO2 nanoparticles have 
been used to modulate oxidative stress in biological systems by acting as free radical 
scavengers [20]. In vitro studies have demonstrated that CeO2 nanoparticles are able to 
rescue HT22 cells (a hippocampus neuronal cell line) from oxidative stress-induced cell 
death [21] and protect normal human breast cells from radiation-induced apoptotic cell 
death [22]. In vivo studies have shown that CeO2 nanoparticles treatment can attenuate 
progressive cardiac dysfunction and remodeling by inhibition of myocardial oxidative 
stress, endoplasmic reticulum stress and inflammation [23]. Whether treatment with 
CeO2 nanoparticles can help to prevent cardiac dysfunction following the development 
of PAH is currently unclear.  
 
Curcumin is a hydrophobic polyphenol compound extracted from turmeric, the 
powdered rhizome of Curcuma longa [24]. Turmeric has been used in Ayurvedic 
medicine for centuries to treat inflammatory diseases [25]. Curcumin has been shown to 
exhibit anti-oxidant [26], anti-inflammatory [27], anti-microbial, and anti-carcinogenic 
activities [28]. The anti-inflammatory activity of curcumin is associated with inhibition of 
cyclooxygenase [29] which can block the activation of the NF-kB and activator protein-
1(AP-1) transcription factors [30]. Studies have shown that blockade of NF-kB may 
contribute to curcumin dependent-inhibition of the TNF-α, IL-1β, and IL-6 inflammatory 
cytokines [31]. Furthermore, curcumin significantly inhibiting the generation of ROS and 
nitride radical generation by activated macrophages [32]. The free radical scavenger 
activity of curcumin has also been shown to protect against cyclophosphamide and 
parquat induced lung injury [33]. It is thought that curcumin treatment is associated with 
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decreased•O2
- levels and lipid peroxidases activity. In addition, curcumin exposure has 
also been shown to increase the amount antioxidant enzymes, e.g. superoxide 
dismutase and catalase, in the heart [34]. Finally, recent work has demonstrated that 
curcumin can inhibit the hypertrophy of cultured cardiomyocytes and prevent the onset 
of heart failure in rat models of hypertensive heart disease and myocardial infarction 
[35]. 
 
To date, no studies in either animals or humans have discovered any toxicity 
associated with the use of curcumin even at very high doses (500-8000 mg/day for 3 
months) [36]. In spite of its therapeutic potential, the utilization of curcumin for the 
treatment of various diseases has been hindered due to its fast metabolism and poor 
water solubility [37, 38]. Efforts to circumvent these problems include the development 
of curcumin nano-formulations using liposomes, polymer nanoparticles, and other 
synthetic materials [39]. Recent work has shown that curcumin nano-emulsions 
improved oral bioavailability and therapeutic efficacy in targeted cancer therapy [40, 41]. 
Other work has shown that liposome-encapsulated curcumin is more effective than free 
curcumin in suppression of pancreatic carcinoma [42]. Recent studies have also 
reported that nano curcumin can inhibit NF-kB activation and down regulate the 
expression of the pro-inflammatory cytokines TNF-α, IL-6, and IL-8 [43]. Whether 
treatment with curcumin nanoparticles can help to prevent cardiac dysfunction following 
the development of PAH is currently unclear.  
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SPECIFIC AIMS 
Right ventricular failure is the leading cause of death in patients with PAH [44]. 
PAH is a progressive, fatal disease characterized by an increased pulmonary vascular 
resistance that causes pressure overload of the RV, leading to RV hypertrophy and 
premature death [45]. Monocrotaline (MCT) is a pyrrizolidine alkaloid that causes 
increases in oxidative stress, inflammation and fibrosis of pulmonary vasculature which 
can lead to pulmonary arterial hypertension and RV hypertrophy in laboratory rats [46]. 
 
The objective of this study is to develop new strategies for the treatment of 
pulmonary arterial hypertension and the resultant RV hypertrophy. Recent studies have 
shown that CeO2 nanoparticles exhibit anti-oxidant properties that may be useful for the 
treatment of chronic inflammation [47]. CeO2 nanoparticles have shown to increase the 
life span of neuronal cell lines [20], and to protect cultured cells against the damaging 
effects of radiation [19]. Curcumin has demonstrated anti-oxidant and anti-inflammatory 
properties suggesting to some that this molecule may be useful to treat pulmonary and 
cardiovascular diseases [48]. In vitro, curcumin nanoparticles (Cur NP) have been 
shown to block NF-kB activation and down regulate the expression of the pro-
inflammatory cytokines TNF-α, IL-6, and IL-8 [43].  
 
The central hypothesis of this research is that CeO2 and curcumin nanoparticle 
administration will be associated with decreases in inflammatory oxidative stress, 
diminished pulmonary arterial hypertension and an attenuation of right ventricular 
hypertrophy following animal exposure to MCT. 
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To test our central hypothesis and accomplish the objective of this study two specific 
aims will be pursued: 
 
Specific aim I: To investigate if CeO2 nanoparticle administration is able to attenuate 
monocrotaline-induced pulmonary arterial hypertension and right ventricular 
hypertrophy in Sprague Dawley rats.  
 
Specific aim II: To investigate if systemic administration of Cur NP is able to diminish 
monocrotaline-induced pulmonary arterial hypertension and right ventricular 
hypertrophy in Sprague Dawley rats. 
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CHAPTER II 
REVIEW OF LITERATURE 
The following chapter presents a review of the current literature pertinent to the 
present study. Specifically, the following areas will be addressed: pulmonary arterial 
hypertension, RV hypertrophy, animal models of PAH, diagnosis of PAH, current 
strategies for treatment of PAH, introduction to nanotechnology and cerium oxide 
(CeO2) nanoparticles, biological effects of CeO2 nanoparticles, toxic effects of CeO2 
nanoparticles, curcumin and its applications, the safety and bioavailability of curcumin. 
 
2.1 Pulmonary arterial hypertension (PAH) 
Pulmonary arterial hypertension (PAH) is caused by restricted flow through the 
pulmonary arterial circulation resulting in increased pulmonary vascular resistance 
which can lead to right heart failure [49]. The hemodynamic definition of PAH is rise in 
mean pulmonary arterial pressure >25 mm Hg at rest or >30 mm of Hg during exercise 
[10]. Elevated pulmonary pressure can result from a decrease in arterial lumen diameter 
through a combination of: a) endothelial dysfunction and increased contractility of small 
pulmonary arteries, b) proliferation and remodeling of endothelial and smooth muscle 
cells, and c) in situ thrombosis [50].  
 
PAH may occur primarily as a disease or secondary to various disease 
conditions such as connective tissue diseases, pulmonary and cardiac diseases, 
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infection and inflammation. The nonspecific nature of the symptoms associated with the 
disease often delays accurate diagnosis, making it difficult to diagnose and treat.  
 
The 4th World Health Organization symposium on pulmonary hypertension held 
in 2008 at Dana Point, California served to update the classification of PAH and is used 
as a guide for the clinical assessment and treatment. 
 
WHO Classification of PAH: 
1. Pulmonary arterial hypertension 
1.1 IPAH 
1.2 Heritable 
1.2.1 BMPR2 
1.2.2 ALK1 (With or without hereditary hemorrhagic telangiectasia) 
1.2.3 Unknown 
1.3 Drug and Toxin induced 
1.4 Associated with 
1.4.1 Connective tissue diseases 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart diseases 
1.4.5 Schistosomiasis 
1.4.6 Chronic hemolytic anemia 
1.5 Persistent pulmonary hypertension of the newborn 
1.6 Pulmonary veno-occlusive disease (PVOD) and/ or Pulmonary capillary 
hemangiomatosis (PCH) 
2. Pulmonary hypertension owing to left heart disease 
2.1 Systolic dysfunction 
2.2 Diastolic dysfunction 
2.3 Valvular disease 
3. Chronic obstructive pulmonary disease 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial drug disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4 Sleep disordered breathing 
3.5 Chronic exposure to high altitude 
3.6 Developmental abnormalities 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
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5.1  Hematologic disorders : Myelo-proliferative disorders, splenectomy 
5.2 Systemic disorders: Sarcoidosis, pulmonary Langerhans cell histiocytosis: 
lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
5.3 Metabolic disorders: glycogen storage disease, Gaucherdisesase, thyroid 
disorders 
5.4 Others: tumoral obstruction, fibrosingmediastinitis, chronic renal failure on 
dialysis 
 
ALK1 = activin receptor-like kinase type-1; BMPR2 = bone morphogenetic protein 
receptor type=2; HIV = human immunodeficiency virus; IPAH=Idiopathic pulmonary 
arterial hypertension 
 
Table 2-1. The updated clinical classification of pulmonary hypertension from 
Dana point, 2008. Adapted from Simonneau et al. 2009 [45], Ryan JJ et al., 2012 [51]. 
 
Symptoms associated with PAH: 
The early phases of PAH may be asymptomatic or associated with non-specific 
symptoms. Patients usually present with dyspnea exacerbated by exertion, fatigue, 
chest pain, and palpitations. Advanced PAH may present as right side heart failure, 
dizziness, syncope, edema or cyanosis [52]. 
 
The normal pulmonary vasculature is a low resistance, high flow system. In PAH, 
the vessel occlusion leads to a persistent elevation in pulmonary pressure that can lead 
to right heart failure. The progressive reduction in cardiac output results in exercise 
intolerance, shortness of breath, fluid retention, and possible death from right heart 
failure [53].   
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Clinical presentation 
Class I: Patients with PAH that causes no limitations on physical activities. Routine 
physical activity does not cause increased dyspnea, chest pain, fatigue, or pre-syncope. 
 
Class II: Patients with PAH that causes mild limitations on physical activities. Patients 
are comfortable at rest but routine physical activity results in increased dyspnea, chest 
pain, fatigue, or syncope. 
 
Class III: Patients with PAH that have marked limitations on physical activities. Patients 
are comfortable at rest, but less than routine physical activity results in dyspnea, chest 
pain, fatigue, or palpitations. 
 
Class IV: Patient with PAH that results in the inability to perform any physical activity 
without symptoms. These patients may have signs of right heart failure. Dyspnea with or 
without fatigue may be present at rest, and symptoms are increased by any physical 
activity. 
Table 2-2. World Health Organization Functional Class of PAH. Adapted from 
Jeanne Houtchens et al., 2011[5]. 
 
2.2 Epidemiology 
A national study examining PAH patients between 1980 to 2002 [54] indicated 
that PAH affects just over 15 per million people [55]. The mean age of those affected 
was 53±14 years at the time of diagnosis, of which 79.5% were women. The mean 
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duration between onset of symptoms and disease diagnosis was 2.8 years [56]. The 
Registry to EValuate Early And Long-term PAH disease management (REVEAL 
Registry) reported that IPAH that occurs with neither a family history of PAH nor an 
identified risk factor associated clinical condition and that IPAH accounts for > 40% of all 
PAH diagnoses in USA [56].  
 
PAH associated with underlying systemic disease is present in approximately 
50% of those diagnosed with PAH. PAH oftentimes develops as a consequence of 
chronic obstructive pulmonary diseases, hypoxia, congenital heart disease and portal 
hypertension. Connective tissue diseases such as scleroderma account for 11-35% of 
PAH cases [57] while 1 to 10% of patients with portal hypertension go on to develop 
PAH [55].  
 
Although there are many factors involved in the pathogenesis of PAH, recent 
data has suggested that increases in oxidative stress and inflammation may be a 
primary driver of PAH development and progression of PAH [9]. Oxidative stress is most 
commonly defined as an imbalance between the production and scavenging of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) [58]. This imbalance can 
alter cellular homeostasis through either direct oxidative and often irreversible damage 
of basic cellular components (proteins, lipids, and nucleic acids), which can impair cell 
function and lead to cellular apoptosis, tissue damage, and vasculopathy.  
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2.3 Right ventricular hypertrophy 
Myocardial hypertrophy is a compensatory mechanism where the cardiac tissue 
adapts to increased work load. In PAH, elevations in pulmonary vascular resistance 
(PVR) lead to the development of pressure overload and RV hypertrophy [59]. 
Depending on the degree or duration of increased work load, ventricular hypertrophy 
may progress from a compensatory state to impaired systolic or diastolic function and 
heart failure. This transition is characterized by alterations in extracellular matrix 
composition, energy metabolism, changes in myofilament protein expression, 
dysregulation of Ca+2 handling, and the activation of different signal transduction 
pathways [60]. 
 
Molecular markers of cardiac hypertrophy 
Myosin and myofibrillar ATPase activity are reduced in the hypertrophied 
myocardium. In the pathological hypertrophy there is a shift from α-MHC to β-MHC and 
from cardiac to skeletal actin isoform expression [61]. The α-MHC form has a three to 
seven fold greater ATPase activity than β-myosin. It is thought that an increase in the 
abundance in β-MHC increases the efficiency of force development as it requires less 
ATP to develop the same amount of muscle tension [62]. RV myocyte hypertrophy also 
stimulates the expression of thyroid degrading enzyme D3 which functions to reduce 
cellular metabolism [63]. 
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Oxidative stress in RV hypertrophy 
It is well established that elevations in ROS may be related to the development of 
the cardiac hypertrophy, changes in blood vessel structure and function, and 
inflammation seen with PAH [64]. Increased ROS levels have been shown to stimulate 
myocardial growth, matrix remodeling and induce cellular apoptosis [65]. It is thought 
that increases in NADPH oxidase, xanthine oxidase and nitric oxide synthase activity 
are a major source of ROS in PAH [66]. ROS also have potent effect on the 
extracellular matrix, stimulating increased accumulation of fibronectin and collagen and 
activating the matrix metalloproteinases [67, 68].  
 
2.4 Animal models 
The etiology and molecular events associated with PAH have been widely 
studied using animal models. The two most common animal models are the use of 
monocrotaline to induce PAH and the chronic hypoxia model of PAH.  
 
2.4.1 Monocrotaline injury model 
Monocrotaline (MCT) is a pyrrolizidine alkaloid from the seeds of Crotalaria 
spectabilis. The MCT model was introduced more than 40 years ago by Lalich and co-
workers [69]. In this model, PAH is typically induced by a single injection of MCT (60 
mg/kg intraperitoneal or subcutaneous injection). The reactive metabolite MCT pyrrole 
is bioactivated in the liver by CYP3A4 [70], which cause pulmonary mononuclear 
vasculitis and severe pulmonary vascular disease [71]. The MCT rat model is widely 
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used given its technical simplicity, reproducibility, and low cost compared to other 
models. 
 
2.4.2 Chronic hypoxia model 
Exposure of animals to low levels of oxygen results in alveolar hypoxia. A 
reduction of the alveolar oxygen pressure to <70 mm Hg elicits strong pulmonary 
arterial vasoconstriction [72]. In the laboratory chronic exposure of animals to hypobaric 
hypoxia has been used to induce pulmonary vascular remodeling leading to PAH [73]. 
This model is widely used because it is very predictable and reproducible within a 
selected animal strain. One limitation of this model is that the responses are significantly 
affected by age as the response is much greater in immature animals than in adults 
[74]. 
 
2.5 Diagnosis 
A high index of suspicion, a meticulous history and a careful physical 
examination are paramount to the diagnosis of PAH. Suspicion is increased by the 
presence of increasing dyspnea on exertion in a patient [75]. A comprehensive 
evaluation of pulmonary function is necessary for the accurate diagnosis of PAH. Other 
diagnostic tools include echocardiography, and serological tests to examine for markers 
of connective tissue remodeling [76]. 
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2.5.1 Six-Minute-Walk Test 
The 6-min-walk test is a sub-maximal exercise test in which the patient walks as 
far as possible in 6 min. During this test, oxygen saturation, heart rate, and distance 
walked are measured. The 6-min-walk test is oftentimes used in the initial patient 
workup to assess exercise performance and predict prognosis [77]. 
 
2.5.2 Echocardiography 
If PAH is suspected, transthoracic echocardiography is used to evaluate the right 
heart hemodynamics including pulmonary arterial pressure, tricuspid regurgitation 
velocity, right heart chamber dimensions, interventricular septum width, RV wall 
thickness, and whether the pulmonary artery is dilated [78]. ECG may provide 
suggestive or supportive evidence of PAH by demonstrating RV hypertrophy and right 
atrial dilatation. 
 
2.5.3 Cardiac magnetic resonance and high resolution computed tomography 
In addition to echocardiography, cardiac magnetic resonance imaging is often 
employed for the assessment of PAH since it can provide a direct evaluation of RV size, 
morphology, and function, while it also allows for a non-invasive assessment of stroke 
volume, cardiac output, pulmonary artery distensibility, and RV mass [79]. Similar to 
magnetic resonance imaging, high-resolution computed tomography is another non-
invasive technology that is used to provide detailed views of the lung parenchyma for 
the diagnosis of interstitial lung disease and emphysema [80].  
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2.5.4 Right heart catheterization 
Right heart catheterization is required to confirm the diagnosis of PAH and to 
assess the severity of the hemodynamic impairment [81]. Right-heart catheterization is 
used to directly measure pulmonary-artery pressure and for the estimation of pulmonary 
vascular resistance [57]. 
 
2.6 Current strategies for treatment of PAH 
The first line therapy for PAH is supportive health care consisting of oxygen 
supplementation, administration of calcium channel blockers and diuretics, and 
recommendations to avoid physical exertion [82]. 
 
Prostacyclin therapy 
Prostaglandin I-2 is a metabolite of arachidonic acid that is produced by the 
vascular endothelium. It is a potent vasodilator, inhibits platelet aggregation, and 
exhibits anti proliferative effects [83]. One of the most successful strategies for PAH 
treatment has been to augment endogenous prostacylin production with exogenous 
prostanoids [10]. Intravenous prostacylin (epoprostenol) for the treatment of PAH was 
approved by the FDA in 1995 and has been shown to decrease pulmonary vascular 
resistance, increase cardiac output, and improve life expectancy [84]. Other drugs 
similar to epoprostenol include Iloprost, which is inhaled, treprostinil which is taken 
subcutaneously, and the oral agent beraprost. 
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Endothelin-A receptor antagonists 
Endothelin-1 is a vasoconstrictor and smooth muscle mitogen that is over 
expressed in the lungs of patients with PAH [85]. Bosentan and ambrisentan are FDA 
approved endothelin receptor antagonists commonly used for the treatment of PAH. 
Bosentan was approved in 2001 and functions as a combined Endothelin-A and 
Endothelin-B receptor antagonist. Bosenten has been found to decrease pulmonary 
vascular resistance and increase cardiac output in PAH patients [86]. Ambrisentan was 
FDA approved in 2007 and is available as once a day oral therapy only for idiopathic 
PAH, heritable PAH and connective tissue disease-PAH [87]. Ambrisentan blocks only 
the Endothelin-A receptors and similarly to bosentan has been shown to significantly 
decrease pulmonary vascular resistance in PAH patients [87]. 
 
Phosphodiesterase-5 (PDE-5) inhibitors, calcium channel blockers and 
antioxidants 
Inhibition of the cGMP-degrading enzyme phosphodiesterase type-5 results in 
vasodilatation through the NO/cGMP pathway [88]. Since the pulmonary vasculature 
contains substantial amounts of phosphodiesterase type-5 enzyme, the potential clinical 
benefit of phosphodiesterase type-5 inhibitors for the treatment of  PAH appear to be 
well justified [89]. Currently sildenafil and tadalafil are FDA approved oral PDE-5 
inhibitors for the treatment of PAH. Sildenafil, approved in 1998, is typically taken three 
times daily orally [90]. Tadalafil, approved in 2003, is available as once daily oral 
therapy for idiopathic and connective tissue disease PAH [91]. 
19 
 
McLaughlin and colleagues demonstrated that the calcium channel blockers 
nifedipine and diltiazem can be used to diminish pulmonary vascular resistance and 
prolong PAH patient survival [92]. In rats, compounds with antioxidant properties such 
as N-acetylcysteine [93], resveratrol [94], superoxide dismutase [95, 96] SOD mimetic 
tempol [97] and EUK-134 [98] have been found to inhibit PAH and or/ RV dysfunction. 
 
2.7 Introduction to Nanotechnology 
Nanotechnology is study of manipulating matter on an atomic and molecular 
scale [99]. The National Nanotechnology Initiative (NNI) defines nanoparticles as 
particulate matter that range in size between 1 and 100 nm (Figure 2-1). Nanomaterials, 
unlike their bulk counterparts, oftentimes exhibit unique electronic, optical and catalytic 
properties [100]. 
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Figure 2-1.The illustration shows visual examples of the size and the scale of 
nanotechnology. (Adopted from www.nano.gov ) 
 
Recent advances in nanotechnology have resulted in the development of various 
engineered nanomaterials including carbon-based nanotubes, C60 -Bucky balls, metal 
oxide nanoparticles, and the nano-encapsulation of drugs [101]. Nanoparticles, given 
their large surface to volume ratio, are characterized by increased surface reactivity 
[102].  
 
Nanomedicine is the application of nanotechnology to medicine. Nanomedicine 
includes the development of nanoparticles and nanostructured surfaces as well as 
nanoanalytical techniques for the diagnosis and treatment of disease. Nanomaterials 
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used in medicine include quantum dots, liposomes, multifunctional constructs and gold 
nanoparticles [103]. It is thought that nanotechnology will contribute significantly to the 
“find, fight, and follow” concept of early diagnosis, therapy and follow-up in medicine 
and that nanotechnology will be a key contributor to the future of medical care [104]. 
 
2.8 Cerium oxide nanoparticles 
Cerium has several unique properties among the rare earth elements and is used 
in the production of oxide fuel cells, ultraviolet absorbents, oxygen sensors, and 
automotive catalytic converters [105]. The cerium atom can easily transition from either 
the +3 (fully reduced) or +4 (fully oxidized) state in several types of redox reactions [15], 
which allows it to act as a catalyst [16].  
 
Ce+3                          Ce+4 + e- 
Ce+3+OH.           Ce+4+OH- 
Ce+4+O2
.-           Ce+3 +O2 
 
The oxidation state of CeO2 can change in response to alterations in 
environmental temperature, the presence of other ions, and oxygen partial pressure 
[106]. Investigations of nanocrystalline cerium oxide (CeO2) have demonstrated an 
increase in the Ce+3valance state and radical scavenging ability with decreasing particle 
size [102]. 
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Figure 2-2.The fluorite structure of cerium oxide. (Adopted from Ali Bumajdad et al., 
2009). 
 
Recently, several researchers have begun to investigate the use of CeO2 
nanoparticles for biomedical purposes. Rzigalinski and coworkers demonstrated that 
CeO2 nanoparticles smaller than 20 nm in size were able to prolong the lifespan of 
cultured neuronal cells, with some cultures remaining still viable even after 6-8 months 
[107]. Chen and colleagues reported that nanoceria particles prevented increases in 
cellular ROS levels in primary rat retina cells and that the use of nanoceria in vivo 
prevented loss of vision due to light induced degeneration of photo receptor cells in 
albino rats [106]. Taken together, these data suggested that nanoceria may be useful 
for preventing ocular degeneration. Schubert and coworkers showed that cellular 
treatment with cerium or yttrium oxide nanoparticles was able to rescue HT22 cells from 
oxidative stress induced cell death by functioning as antioxidants [21].  
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Recent in vivo experiments conducted by Niu and colleagues reported that CeO2 
nanoparticles diminished the degree of cardiac dysfunction and remodeling in MCP-1 
transgenic mice by attenuating the development of myocardial and ER oxidative stress 
[23]. Similarly, CeO2 nanoparticles have also been capable of protecting lung fibroblast 
cells from radiation induced damage in vitro and in vivo using athymic nude mice [108]. 
 
It is thought that CeO2 nanoparticles function to protect cells and tissues through 
their ability to scavenge ROS. Indeed, Hirst and coworkers using murine macrophage 
cells (J774A.1) showed treatment with CeO2 nanoparticles reduced superoxide anion 
levels and that this reduction in superoxide was associated with decreased expression 
of inducible nitric oxide synthase (iNOS) and inflammation [22]. Likewise, Estevez and 
colleagues, using an in vitro model of brain ischemia, demonstrated that nanoceria 
treatment was associated with neuroprotective effects and that this effect was 
associated with increased scavenging of peroxynitrite. 
 
Kong and coworkers showed that nanoceria could protect against retinal 
degeneration in tubby mice by decreasing ROS production, up-regulating the 
expression of neuroprotective genes, and by inhibiting the activation of caspase-
induced apoptotic signaling pathways [109]. CeO2 nanoparticles have also be shown to 
protect against monocrotaline-induced hepatic toxicity by virtue of their ability to 
increase the amount of glutathione reductase, glutathione, and glutathione peroxidases 
[110]. 
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 Toxic effects of CeO2 nanoparticles 
 The potential hazardous health effects of nanoparticles are an emerging issue 
amongst toxicologists and regulatory authorities. Given the extensive use of cerium 
oxide nanoparticles in the glass polishing, the electronics industry, and use as a diesel 
fuel additive, interest regarding the potential toxicity of these particles has intensified 
[111]. Indeed, although the literature has demonstrated the CeO2 nanoparticles can 
promote cell survival under conditions of oxidative stress it is likely that these 
nanoparticles also exhibit toxic effects if cellular exposure is excessive. 
 
In vitro studies by Lin and colleagues using human branchoalveolar cells (A549 
cells) demonstrated that exposure to 20-nm CeO2 nanoparticles was associated with 
the generation of free radicals, increased lipid peroxidation, and cell membrane damage 
that led to reduced cell viability [112]. Park and coworkers showed that CeO2 
nanoparticles exposure caused the induction of ROS in cultured human lung epithelial 
cells (BEAS-2B) and that increases in cellular ROS were associated with decreased 
levels of intracellular glutathione (GSH) and reduced cell viability [113]. 
 
Similar findings have been demonstrated in vivo. Using male Sprague Dawley 
rats, Ma and colleagues demonstrated that the intratracheal instillation of cerium oxide 
nanoparticles induced acute pulmonary inflammation and chronic lung injury [114]. 
Follow up studies by these same researchers showed that lung injury caused by cerium 
oxide nanoparticles was due to increased ceria deposition in the lung, increased 
pulmonary fibrosis and an up-regulation of fibrogenic cytokines [111]. 
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More recently, Nalabotu and co-workers found that the intratracheal instillation of 
CeO2 nanoparticles was associated with the accumulation of ceria in the liver, the 
hydropic degeneration of hepatocytes, dilatation of sinusoids, and elevations in serum 
liver enzyme level [115]. 
 
2.9 Curcumin 
Curcumin is a constituent of turmeric, a curry powder extracted from the plant 
Curcuma longa that belongs to the Zingiberaceae family (Figure 2-3). Turmeric is native 
to India and Southeast Asia, and is used in cooking to add color. The ability of curcumin 
to preserve food is well known. Indian Ayurvedic medicine has used turmeric for 
centuries to treat biliary disorders, anorexia, cough, diabetic wounds, liver disorders, 
rheumatism, and respiratory conditions [116]. Turmeric also exhibits haemostatic-like 
activity and is also anti-inflammatory in nature [117].  
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Figure 2-3. Curcuma longa plant. Inserts show the flower (a.), rhizome (b.) 
and turmeric powder (c.). (Adopted and modified from Seema Singh 2007). 
 
Curcumin is a hydrophobic polyphenol compound with a characteristic yellow 
color. The chemical structure of curcumin is a bis-α, β-unsaturated β-diketone. It is 
characterized by two oxy-substituted aryl moieties that are linked together through by a 
seven carbon chain [118] (Figure 2-4). 
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Figure 2-4.Structure of curcumin (diferuloylmethane) 
 
Applications of curcumin 
Curcumin possesses several pharmacological properties including anti-
inflammatory [119], antioxidant [120], antimicrobial [121], chemo sensitizing [122], anti-
neoplastic [123], and wound healing activities [124]. Curcumin has proven to be 
beneficial in the prevention and treatment of a number of inflammatory diseases 
possibly due to its ability to inhibit the inflammatory mediators cyclooxygenase (cox-2) 
and lipoxygenase-5 at the transcriptional level [125]. The free radical scavenging activity 
of curcumin due to the presence of H-atom donation and resonance stabilization from 
two  phenolic OH groups and from the electron transfer capacity of β-diketone moiety. In 
addition, curcumin also down-regulates the expression of several pro-inflammatory 
cytokines including tumor necrosis factor (TNF-α), the interleukins (IL-1, IL-2, IL-6, IL-8, 
IL-12) and some chemokines, most likely through inactivation of the nuclear 
transcription factor NF-κB [126, 127] (Figure 2-5).  
 
The transcription factor NF-κB is thought to play a critical role in the resistance of 
cancer cells to chemo and radiation therapy as it can prevent the induction of apoptosis 
[128]. In recent experiments Deeb and coworkers demonstrated that curcumin 
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sensitizes prostate cancer cells to TNF-related apoptosis inducing ligand (TRAIL)-
induced apoptosis through the inhibition of NF-κB [122]. Other data has shown that 
curcumin can induce cell cycle arrest and/or apoptosis in human cancer cell lines 
derived from a variety of solid tumors including colorectal, lung, breast, pancreatic and 
prostate carcinoma [129]. 
 
 
Figure 2-5.Molecular targets of curcumin. (Adopted and modified from Bharat 
B. Aggarwal et al., 2009 [28] ). 
In addition to its anti-cancer properties, curcumin is also widely known to possess 
potent antioxidant activity as it is able to scavenge several different types of ROS 
including O2 −, OH , NO  and ONOO  radicals [126]. In addition, Manikandan and 
colleagues have shown that exposure to curcumin can also increase the activity of 
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superoxide dismutase, catalase and glutathione peroxidases [34]. It is thought that the 
antioxidant activity of curcumin is attributed to its phenolic and methoxy groups [130]. 
 
The antibacterial effects of curcumin have been reported by K.S. Parvathy and 
colleagues where they showed that curcumin suppressed the growth of Streptococcus, 
Staphylococuus, E.coli, and Y.enterocolitica. Ronita De and coworkers using a mouse 
model demonstrated that curcumin also inhibited the growth of Helicobacter pylori both 
in vitro and in vivo. Whether curcumin exhibits antibacterial activity against other strains 
is currently under investigation.  
 
Safety 
Animal and human clinical studies have shown that curcumin is extremely safe 
even at doses as high as 12gm/day [131]. Recent phase-1 clinical trials have shown 
that curcumin is not toxic to humans when administered at 8gm/day for up to 3 months 
[132]. On the basis of these studies and others [131, 133], curcumin  is generally 
recognized as safe (GRAS) by the United State’s FDA and has been granted an 
acceptable daily intake level of 0.1–3 mg/kg body weight by the Joint FAO/WHO Expert 
Committee on Food Additives, 1996 [134]. 
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Bioavailability 
A major limiting factor of curcumin use for biomedical purposes is its solubility 
and low oral bioavailability [135, 136]. The factors responsible for the low bioavailability 
of curcumin are not fully understood but are likely related to the poor absorption from 
the gut, the rapid metabolism and its rapid systemic elimination [137]. The serum 
concentration of curcumin has been found to peak at 1–2 h after oral intake and to 
gradually decline thereafter [138]. Curcumin undergoes glucuronidation and sulfation in 
the liver [139]. The metabolites of curcumin for the most part appear to lack any 
pharmacological activity [28]. The addition of piperdine, which functions to inhibit the 
glucronidation of curcumin, has been shown to increase curcumin bioavailability in rats 
and in human subjects by at least one order of magnitude [140]. 
  
 In addition to piperdine supplementation, the bioavailability of curcumin could 
also be increased by protecting it from degradation. Various nano-formulations have 
been formulated for this purpose including PLGA nanoparticles (Nano-CUR) [141] 
liposomal nano-curcumin [42], curcumin loaded magnetic nanoparticles [142], curcumin 
nano-emulsions [40], and solid lipid nanoparticles [39]. Indeed, the entrapment of 
curcumin into nanoparticles led to a 9-fold increase in oral bioavailability when 
compared to that observed when curcumin was administered orally in bulk form [143]. 
This increase in bioavailability is thought to be due to improved water solubility, a higher 
release rate in the intestinal juice, enhanced permeability and absorption by the small 
intestine, and increased residence time in the intestinal cavity [144]. Wang and 
coworkers demonstrated that liposomal encapsulated curcumin suppressed NF-κB 
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activation and attenuated the proliferation of human pancreatic carcinoma cells [145]. 
Supporting this contention, Bisht and colleagues showed that nano curcumin, like its 
bulk counterpart, inhibited the activation of the transcription factor NF-κB, and that this 
inhibition was associated with reduced levels of pro-inflammatory cytokines (IL-6, IL-8) 
and TNF-α in human pancreatic cancer cell lines [43]. 
 
3.0 Summary 
In summary, this review of literature described pulmonary arterial hypertension 
and RV hypertrophy. PAH is an increase in pulmonary arterial pressure due to 
obliteration of small pulmonary arteries causing an increase in pressure overload on the 
RV leading to RV failure and death [1, 52]. Currently, there is no cure for the patients 
suffering from PAH [5]. Increased markers of oxidative stress have been found in 
human as well as in animal models of PAH supporting the evidence that ROS and RNS 
play a major role in the development and progression of PAH [50]. Thus far, several 
antioxidants including N-acetylcysteine, resveratrol and the synthetic antioxidant EUK-
134 have been tested for their efficacy in preventing the progression of PAH in animal 
models.  
 
Cerium is a rare earth element of the lanthanide series, having a fluorite lattice 
structure with oxygen vacancies or defects in the lattice structure by loss of oxygen or 
its electrons. At the nanometer scale, the atomic and molecular properties of nano 
materials will change. Studies have demonstrated that decreases in CeO2 nanoparticles 
size are associated with the formation of more oxygen vacancies [18]. Recent studies 
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have shown that CeO2 nanoparticles have been shown to protect against cardiac 
dysfunction by attenuating myocardial oxidative stress and the inflammatory process in 
transgenic mice through the autoregenerative antioxidant capacity. 
 
Curcumin, a polyphenolic compound with neuroprotective, cardio protective, anti-
oxidant and anti-inflammatory properties, has been used for centuries in Ayurveda, an 
Indian traditional medicine, to treat a diversity of disorders including rheumatism, body 
aches, skin diseases, wounds, intestinal worms, diarrhea, intermittent fevers, hepatic 
disorders, urinary discharges, dyspepsia, and inflammation. For the past two decades, 
curcumin has been extensively studied as a potent anti-oxidant due to its ability to 
scavenge ROS and an anti-inflammatory agent due to its down regulation of pro 
inflammatory cytokines and transcription factors [126].  
Whether ceria or curcumin nanoparticles are effective for the treatment of PAH is 
currently unclear.  
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CHAPTER III 
 
The following chapter includes three different research papers describing in detail 
the research experiments conducted to test our hypotheses set forth for the specific 
aims I and II of this dissertation project. 
 
PAPER 1 
The following paper corresponds to the specific aim I  
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Cerium oxide nanoparticles attenuate monocrotaline-induced right ventricular 
hypertrophy following pulmonary arterial hypertension 
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Efficacy of cerium oxide nanoparticles on right ventricular hypertrophy following 
pulmonary arterial hypertension. 
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Abstract 
Introduction: Cerium oxide (CeO2) nanoparticles have been shown to exhibit 
potent antioxidant activity and recent data has suggested that these materials may 
attenuate oxidative stress-induced cardiomyopathy. Here, we investigate whether CeO2 
nanoparticle administration can diminish the amount of right ventricular hypertrophy 
developed following monocrotaline (MCT)-induced pulmonary arterial hypertension 
(PAH) in the laboratory rat. Methods: Male Sprague Dawley rats (175-200 gm) were 
randomly divided into control, MCT only and MCT + CeO2 nanoparticle groups (n=6). 
MCT animals received a single injection of MCT 60 mg/kg subcutaneously to induce 
PAH. CeO2 treated animals were given 0.1 mg/kg CeO2 nanoparticles intravenously 
twice a week for 2 weeks. Echocardiography was done at the start of the study and 28 
days after MCT injection to assess pulmonary, cardiac structure and function. Results: 
Compared to control rats, the right ventricle weight to body weight ratio was 45% and 
22% higher in the MCT and MCT + CeO2 rats, respectively (p<0.05). Echocardiography 
data demonstrated that CeO2 nanoparticle treatment appeared to attenuate 
monocrotaline-induced changes in pulmonary flow and increases in right ventricle wall 
thickness. Immunoblotting analysis demonstrated that CeO2 nanoparticle treatment 
diminished MCT-induced increases in the amount of β-myosin heavy chain and 
fibronectin. CeO2 nanoparticle treated rats also exhibited diminished expression of the 
MAP kinases, decreased TUNEL positive nuclei. These changes were accompanied by 
improvements in the Bax/Bcl2 ratio, and diminished caspase-3 activation. Conclusion: 
Taken together, these data suggest that CeO2 nanoparticle administration may 
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attenuate MCT-induced PAH associated RV cardiomyocytes apoptosis possibly via 
diminishing indices of oxidative stress. (WC: 250) 
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Introduction 
Right ventricular failure is the leading cause of death in patients with pulmonary 
arterial hypertension (PAH) [146]. PAH is defined as an increase in mean pulmonary 
arterial pressure (PAPm) >25mm Hg at rest, or >30mm Hg during exercise [55]. If 
improperly managed, the median life expectancy of patients with idiopathic PAH is 2.8 
years, with 1-year, 3-year, and 5-year survival rates of 68%, 48%, and 34%, 
respectively [2]. Even with modern medical therapy, PAH patients oftentimes 
experience disease progression and eventual referral for organ transplantation [5]. The 
rat monocrotaline (MCT)-PAH model is thought to recapitulate many of the pathological 
features of PAH seen in humans [147]. Recent data has suggested that the cardiac 
remodeling associated with MCT induced-PAH may be mediated, at least in part, by 
increases in oxidative stress [98]. Whether treatments aimed at diminishing oxidative 
stress levels effective in preventing the cardiac hypertrophy seen with PAH is currently 
unclear.  
 
Cerium is a rare earth element of the lanthanide series that can cycle between 
the Ce+3 (fully reduced) or Ce+4 (fully oxidized) state [15]. Recent data has suggested 
that CeO2 nanoparticles can act as free radical scavengers [15] and protect H9C2 
cardiomyocytes from cigarette smoke extract induced oxidative damage [148]. In vivo 
studies using the monocyte chemo-attractant protein-1 (MCP-1) transgenic mouse 
model of oxidative stress-induced cardiac hypertrophy have shown that CeO2 
nanoparticle administration can attenuate the development of cardiac dysfunction and 
remodeling [23]. Supporting these data, other work has shown that the antioxidant 
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activity of CeO2 nanoparticles can protect against monocrotaline-induced hepatic toxicity 
[110]. Whether CeO2 nanoparticle administration can attenuate the development of the 
RV hypertrophy seen during PAH is currently unclear.  
 
Monocrotaline (MCT) is a toxic pyrrolizidine alkaloid present in the plant 
Crotalaria spectabilis that selectively injures lung endothelial cells causing the infiltration 
of monocytes, a thickening of the pulmonary arterioles and the development of PAH in 
the laboratory rat [12, 13]. Here we examine if the administration of CeO2 nanoparticles 
is associated with the attenuation of right ventricular hypertrophy, oxidative stress 
induced ventricular remodeling following monocrotaline induced PAH. Our data suggest 
that CeO2 nanoparticle treatment may be effective for counteracting the hypertrophy 
seen following PAH in the laboratory rat.  
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Materials and Methods 
Animal model and experimental design 
All procedures were performed in accordance with the Marshall University 
Institutional Animal Care and Use Committee (IACUC) guidelines, using the criteria 
outlined by the Assessment and Accreditation of Laboratory Animal Care (AAALAC). 
Seven week old, 175-200 gm, male Sprague Dawley rats were obtained from Hilltop 
laboratories (Scottdale, PA). Rats were housed two per cage with a 12:12H dark-light 
cycle and temperature maintained at 22 ± 2°C. Rats were provided food and water ad 
libitum and allowed to acclimatize for at least two weeks before initiating the study. 
Periodic body weight and feed intake measurements were taken throughout the 
duration of the study. Rats were randomly assigned to one of three different groups: 
Control (n=6), MCT only (n=6), MCT + CeO2 nanoparticle (n=6). PAH was induced by a 
single injection of MCT (60mg/kg S.C.) (Sigma-Aldrich, St.Louis, MO) as described 
previously [149]. Animals injected with MCT were given either CeO2 nanoparticles 
(0.1mg/kg via tail vein) (NanoactiveTM CeO2 nanoparticles, NanoScale materials Inc., 
Manhattan, KS) or vehicle (deionized water) twice a week for the 1st and 2nd week of the 
study. Importantly, there was no toxicity or accumulation observed in vivo at therapeutic 
low doses 0.1 mg/kg and 0.5 mg/kg of CeO2 nanoparticles injected via tail vein as 
reported previously [47]. 
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CeO2 nanoparticle size analysis by Dynamic Light Scattering (DLS) 
The measurement of particle size distribution was done using a LB-550 dynamic 
light scattering (DLS) particle size analyzer (Horiba scientific, Edison, NJ) at Marshall 
University. Briefly, CeO2 nanoparticles were sonicated in deionized water for two 
minutes to ensure equal dispersion. Particle size was performed as outlined by the 
manufacturer and measured in triplicate. 
 
CeO2 nanoparticle analysis using atomic force microscopy (AFM) 
Twenty micro liters of CeO2 nanoparticles (1µg/µl) was placed on freshly cleaved 
mica (V1 mica, SPI Inc, West Chester, PA). After 10 min of incubation, the surface was 
gently rinsed with deionized water to remove unbound CeO2 nanoparticles and the 
surface was dried under nitrogen. Particles were imaged in noncontact mode at a 
frequency of 319 kHz and a scan speed of 0.5 Hz using a Nano-R microscope (Pacific 
Nanotechnology Inc., Santa Clara, CA) equipped with a TM300A noncontact probe 
(SensaProbes Inc., Santa Clara, CA) at MBIC, Marshall University. 
 
Echocardiography 
Echocardiography was performed prior to the start of the study and at day 28 of 
the study at an ICAEL accredited echocardiography laboratory with help of trained 
echocardiography technician in University Cardiovascular services, Marshall University 
as outlined previously [150]. Rats were anesthetized with an intraperitoneal injection of 
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ketamine and xylazine cocktail mixture (50 mg/kg; 4:1) and the ventral thorax area 
shaved. ECG analysis was performed during the echocardiography procedure to 
monitor heart rate. Echocardiography measurements were obtained with a Philips 
Sonos 5500 echocardiogram system using 12-MHZ transducer. M-mode and 2-D 
modalities were used to measure RV and LV wall thickness at the end of diastole using 
the right parasternal long axis view with the ultrasonic beam positioned perpendicular to 
the ventricular wall. Papillary muscles were used as reference point for measurements 
and to assure proper position in subsequent studies. Pulmonary artery flow was 
measured using pulsed wave Doppler at the pulmonary valve level while pulmonary 
artery diameter was measured at the level of pulmonary out flow tract during systole 
using the parasternal short axis view. An apical four-chamber view was employed to 
measure end-diastolic right ventricular area. Pulsed-wave Doppler was used to 
measure pulmonary artery acceleration time and flow.  
 
Tissue processing and immunoblotting 
Animals were anesthetized with ketamine-xylazine (4:1) cocktail mixture 
(50mg/kg, i.p) and supplemented as necessary to achieve loss of reflexive response 
before tissue collection. After mid ventral laparotomy, the heart was removed and 
placed in Krebs–Ringer bicarbonate buffer (KRB) containing 118 mM NaCl, 4.7 mM 
KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 24.2 mM NaHCO3, and 10 mM D-
glucose (pH 7.4) equilibrated with 5% CO2 / 95% O2 and maintained at 37°C. The right 
ventricle was separated from the left ventricle and septum, weighed and immediately 
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flash frozen in liquid nitrogen and stored at -80°C. Lungs were weighed as a measure of 
the degree of pulmonary vasculitis and as an indication of the increase in pulmonary 
arterial pressure [98]. 
  
Frozen right ventricles were homogenized in buffer (T-PER, 10 ml/g tissue; 
Pierce, Rockford, IL, USA) containing protease (P8340, Sigma-Aldrich, St. Louis, MO, 
USA) and phosphatase inhibitors (P5726, Sigma- Aldrich, St. Louis, MO, USA). After 
incubation on ice for 30 min, the homogenate was collected by centrifuging at 12,000 g 
for 5 min at 4°C. Protein concentration of homogenates was determined via the 
Bradford method (Fisher Scientific, Rockford, IL). Homogenate samples were boiled in a 
Laemmle sample buffer (Sigma-Aldrich, St. Louis, MO, USA) for 5 min. Forty 
micrograms of total protein for each sample was separated on a 10% PAGEr Gold 
Precast gel (Lonza, Rockland, ME) and then transferred to nitrocellulose membranes 
using standard methods as detailed elsewhere [151]. Membranes were blocked with 5% 
milk in Tris Buffered Saline (TBS) containing 0.05% Tween-20 (TBST) for 1 h and then 
probed  with primary antibodies for the detection of β-myosin heavy chain (M 8421, 
sigma Aldrich, St. Louis, MO), fibronectin (AB23750, Abcam, Cambridge, MA), (AMPK- 
α (#2532), p-AMPK-α (#2535), Bax (#2772), Bcl2 (#2870s), Caspase-3 (#9662), 
Cleaved caspase-3 (#9661s), ERK 1/2 (#9106s), p-ERK 1/2 (#4377s), p-P-38 (#9216L), 
P-38 (#9212), p-HSP-27 (#24068), HSP-27 (#2442s), HSP-70 (#4872), p-HSP-90 
(#3488), p-JNK (#9251s), JNK (#9252), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (#2118), (from Cell Signaling Technology, Inc., Beverly, MA)) and p-NFkB-
p50 (SC-33022), NFkB-p50 (SC-8414), and 3-nitrotyrosine (SC-55256) (from Santa 
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Cruz Biotechnology, Inc., Santa Cruz, CA). After an overnight incubation at 4°C in 
primary antibody buffer (5% BSA in TBS-T, primary antibody diluted 1:1000) 
membranes were washed with TBST, and then incubated with HRP-conjugated 
secondary antibodies (anti-rabbit (#7074) or anti-mouse (#7076), Cell Signaling 
Technology, Danvers, MA) for 1 h at room temperature. After removal of secondary 
antibody, membranes were washed (3 x 5 min) in TBS-T and protein bands were 
visualized following reaction with ECL reagent (Amersham ECL Western Blotting 
reagent RPN 2106, GE Healthcare Bio-Sciences Corp., Piscataway, NJ). Target protein 
levels were quantified by AlphaEaseFC image analysis software (Alpha Innotech, San 
Leandro, CA) and normalized to (GAPDH). 
 
OxyBlot analysis 
OxyBlot™ Protein Oxidation Detection kit (#S7150, Millipore, MA) was used for 
the immune blot detection of carbonyl groups. Carbonyl groups are introduced into 
proteins due to oxidative reactions by oxygen free radicals and other reactive oxygen 
species [152]. Briefly, 5 μg total protein of each sample was derivatized by reaction with 
2, 4-dinitrophenylhydrazine (DNPH) at room temperature for 15 min before separation 
using 10% PAGEr Gold Precast gels. Oxidized proteins were detected by 
immunoblotting using the anti-DNP antibody provided in the kit [29]. Bands were 
visualized following reaction with ECL reagent (Amersham ECL Western Blotting 
reagent RPN 2106, GE Healthcare Bio-Sciences Corp., Piscataway, NJ). Target protein 
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levels were quantified by AlphaView SA image analysis software (Alpha Innotech, San 
Leandro, CA). 
 
Histological analysis 
a. Dystrophin staining 
RV tissues were serially sectioned (8 μm) using an IEC Microtome cryostat and 
the sections were collected on poly-L-Lysine coated slides. Sections were stained for 
dystrophin immunoreactivity and used to evaluate the cardiomyocyte cross sectional 
area (CSA) as outlined elsewhere [153]. Briefly, sections were incubated for 30 min in a 
blocking solution (5% bovine serum albumin [BSA] and phosphate-buffered saline [PBS] 
containing 0.5% Tween 20 (PBS-T), pH 7.5 and then incubated with specific anti sera 
diluted in PBS-T (anti-dystrophin 1:100, rat-igG 1:100) for 1 h at 37°C in a humidified 
chamber. After washing in PBS-T (3 x 5 min), sections were incubated with the 
appropriate FITC labeled secondary antibody (1:200) for 1 h at 37°C in a humidified 
chamber. Muscle cross sections were visualized by epi-fluorescence using an Olympus 
BX51 microscope (Olympus, Center Valley, PA), fitted with 20x and 40x objectives. 
 
b. Picrosirius red staining  
Picrosirius red staining was used to assess the collagen content deposition in RV 
sections as detailed elsewhere [154]. Briefly, RV frozen tissue sections were fixed with 
95% alcohol for 1 min, washed three times with running tap water, and then stained with 
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hematoxylin for 8 min, and picrosirius red for 20 min. After dehydrating sections and 
mounting, collagen content was visualized at 20x magnification using an Olympus BX51 
microscope (Olympus, Center Valley, PA). 
 
c. Dihydroethidium staining  
RV cardiac muscles were serially sectioned (8 μm) with an IEC Microtome 
cryostat, and the sections were collected on poly-L-lysine coated glass slides. The 
fluorescent superoxide marker dihydroethidium (hydro ehidine) was used to evaluate 
superoxide levels as outlined elsewhere [155]. Upon oxidation, dihydroethidium is 
intercalated within DNA exhibiting a bright fluorescent red [156]. Briefly, RV frozen 
tissue sections were washed with phosphate-buffered saline (PBS) for 5 min and then 
incubated with 200 μl of 10 μM of dihydroethidium (Molecular Probes, Eugene, OR) for 
1 h at room temperature. After washing with PBS (3 x 5 min), fluorescence was 
visualized under a Texas red filter using an Olympus BX-51 microscope (Olympus 
America, Melville, NY, USA) equipped with Olympus WH 20x wide field. Images were 
recorded digitally using a CCD camera and the integrated optical density determined 
using the Alpha view image analysis software (Cell Biosciences, Inc., Santa Clara, CA). 
 
d. TUNEL staining  
DNA fragmentation was determined by TdT-mediated dUTP nick end labeling 
(TUNEL) according to the manufacturer’s recommendations (In Situ Cell Death 
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Detection Kit, Roche Diagnostics, Mannheim, Germany) as described elsewhere [157]. 
Briefly, TUNEL staining was performed on RV tissue sections (8 μm) obtained from 
control (n=3), MCT only (n=3), and MCT + CeO2 nanoparticle treated rats (n=3), which 
were fixed with 4% paraformaldehyde, washed with PBS (pH 7.4), and then 
permeabilized with 0.1% sodium citrate and 0.1% Triton-X. Cross-sections from each 
muscle were treated with DNase I to induce DNA fragmentation as a positive control. 
Heart sections were blocked with 3% BSA and the sections were incubated with the 
TUNEL reaction mixture containing TdT and fluorescein dUTP. Nuclei were counter 
stained using DAPI (VECTASHIELD HardSet Mounting Medium, Vector Laboratories, 
and Burlingame, CA). Fluorescence images were visualized using an Olympus BX-51 
microscope (Olympus America, Melville, NY) equipped with Olympus WH 20x and 40x 
wide fields.  
Serum protein immune assays 
Sera collected during exsanguations were pooled from all six rats in each group 
and sent to Myriad RBM (Austin, TX) for RodentMAP® v 2.0 Antigen analysis using a 
Luminex Lab MAP instrument as detailed elsewhere [19, 115]. Each analyte was 
quantified using 4 and 5 parameter, weighted and non weighted curve fitting algorithms 
using proprietary data analysis software developed at Rules-Based Medicine. 
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Data analysis 
Results are presented as mean ± SEM. Data were analyzed using SigmaPlot 
11.0 computer software. One-way analysis of variance (ANOVA) was used for overall 
comparisons.  The Student Newman Keuls post hoc test was used to determine 
statistical significance. The level of significance accepted a priori was p ≤ 0.05. 
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Results 
Characterization of CeO2 nanoparticles 
CeO2 nanoparticle diameter as determined by DLS and AFM were 300 ± 58 nm 
and 300 ± 25 nm, respectively (Figure 3-1 Panels A, B). 
 
CeO2 nanoparticles treatment decreases right ventricular tissue weight 
Compared to the control animals, body weight in the MCT and MCT + 
CeO2animals was 14% and 13% less, respectively (P< 0.05, Table 3-1). Conversely, 
the ratio of heart weight to body weight was 22% and 4% higher in the MCT and MCT + 
CeO2 animals (P< 0.05). Similarly, the ratio of right ventricle (RV) weight to body weight 
ratio was 83% and 29% higher in the MCT and MCT + CeO2 nanoparticle animals (P< 
0.05), while the wet lung weight to body weight ratio was 48% and 36% higher in the 
MCT and MCT + CeO2 nanoparticle animals (P< 0.05). 
 
CeO2 nanoparticles treatment decreases MCT-induced changes in pulmonary 
arterial pressure and cardiac remodeling 
Compared to the MCT + CeO2 nanoparticle animals, echocardiographic analysis 
of pulmonary arterial flow demonstrated a mid-systolic notch in the MCT animals (Figure 
3-2, Panel B). Consistent with this finding, pulmonary arterial pressure (PA Pr) was 18% 
higher in MCT while PA Pr was equal to the base line measurement in the MCT + CeO2 
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animals (Figure 3-3, Panel A P<0.05). Mean pulmonary arterial diameter was 27% and 
1% higher in MCT and MCT + CeO2 nanoparticle animals, respectively (Figure 3-3, 
Panel B, P<0.05). Supporting these data, the mean pulmonary arterial area was 46% 
higher in the MCT animals but only 3% greater in the MCT + CeO2 nanoparticle animals 
(Figure 3-3, Panel C, P<0.05). Similarly, the right ventricular outflow tract diameter was 
14% and 1% higher in MCT and MCT + CeO2nanoparticle animals (Figure 3-3, Panel D, 
P<0.05). Similar to our findings at the whole tissue level, echocardiography analysis 
demonstrated that CeO2 nanoparticle treatment attenuated MCT-induced increases in 
RV anterior free wall thickness (Figure 3-4). Likewise, the interventricular septum 
diameter was 16% higher in MCT animals but only 3% greater in the MCT + CeO2 
animals (Figure 3-5, Panel B, P<0.05). 
 
In the MCT only animals, the echocardiography analysis showed that the right 
atrium septum tended to bow toward the left atrium (Figure 3-6, Panel A). Similarly, in 
MCT animals a D-shaped inter-ventricular septum, septal flattening and tricuspid 
regurgitation was observed (Figure 3-6, Panels B, C), which are all consistent with 
advanced PAH and RV hypertrophy.  
 
To examine the molecular alterations that might accompany PAH-induced 
changes in RV thickness we next performed dystrophin immunofluoresence staining to 
determine the average cardiomyocyte cross sectional area (CSA) in the right ventricle. 
Compared to the control animals, ventricular CSA was 34% higher in the MCT animals 
but only 1% greater in the MCT + CeO2 group (Figure 3-7, Panels A, B, C, D, P<0.05). 
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Although not quantitated, picrosirius red staining suggested that the degree of MCT-
induced collagen deposition was less in the CeO2 treated animals when compared to 
that in the MCT only animals (Figure 3-7, Panel G). 
 
In an effort to extend these findings, we next performed immunoblotting to 
examine the effect of CeO2 nanoparticle treatment on myosin heavy chain expression. 
Compared to control animals, MHC-β expression was 91% higher in the MCT animals 
but only 3% higher in MCT + CeO2 group, respectively (Figure 3-8, Panel B, P<0.05). 
Similarly, MCT-induced fibronectin expression was 113% higher in the MCT animals but 
only 4% more in the MCT + CeO2 animals (Figure 3-8, Panel A, P<0.05). 
 
CeO2 nanoparticles treatment decreases MCT-induced increases in oxidative 
stress signaling 
As an index of oxidative stress, we determined superoxide anion levels in tissue 
sections obtained from the RV by quantifying dihyroethidium (DHE) fluorescence levels. 
Compared to the control rats, the DHE fluorescence intensity was 71% and 12% higher 
in the MCT and MCT + CeO2 nanoparticle treatment rats, respectively (Figure 3-9, 
P<0.05). In an effort to extend these findings, we next examined the effects of PAH and 
treatment on the amount of protein exhibiting 3-nitrotyrosine (3-NT) modification. 
Compared to the control rats, 3-NT levels were 15% higher in the MCT animals (Figure 
3-10, Panel A, P<0.05). Interestingly, CeO2 nanoparticle treatment actually reduced 3-
NT levels by 17% compared to that observed in the control animals (Figure 3-10, Panel 
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A, P<0.05). Likewise, compared to control rats, the amount of protein carbonylation was 
14% and 4% higher in the MCT and MCT + CeO2 groups, respectively (Figure 3-10, 
Panel B, P<0.05). 
 
CeO2 nanoparticles treatment attenuates MCT-induced increases in AMPK alpha, 
ERK1/2 and JNK phosphorylation  
Compared to the control rats, the amount of p-AMPK alpha was 9% higher and 
MCT animals and 11% lower in the MCT + CeO2 group (Figure 3-11, Panel A, P<0.05). 
Total AMPK alpha levels were 1% and 9% lower in the MCT and MCT + CeO2 
nanoparticle treated rats, respectively  (Figure 3-11, Panel A, P<0.05). Compared to the 
control rats, the amount of p-ERK 1/2 protein was 17% higher and 7% lower in MCT 
and MCT + CeO2 animals, respectively (Figure 3-11, Panel B, P<0.05). Total ERK 1/2 
was 12% and 2% higher in the MCT and MCT + CeO2 nanoparticle treatment rats, 
respectively (Figure 3-11, Panel B). 
 
Compared to the controls, p-JNK levels were 19% and 11% higher in the MCT 
and MCT + CeO2 rats, respectively (Figure 3-11, Panel C, P<0.05). Total JNK protein 
was unchanged and 6% higher in the MCT and MCT + CeO2 nanoparticle treatment 
rats, respectively (Figure 3-11, Panel C).  
  
In an effort to extend these findings, we next examined the effect of CeO2 
nanoparticle treatment on the regulation of HSP-27 following MCT insult. Compared to 
52 
 
the control rats, the amount of p-HSP-27 was 88% and 9% higher in the MCT and MCT 
+ CeO2 groups, respectively (Figure 3-12, Panel A, P<0.05). Similarly, total HSP-27 
levels were 55% and 15% higher in the MCT and MCT + CeO2 nanoparticle treatment 
rats, respectively (Figure 3-12, Panel B). No changes in the expression and 
phosphorylation levels of HSP-70 and HSP-90 were observed (Data not shown). 
 
CeO2 nanoparticles treatment attenuates MCT-induced increases in the 
expression of NF-kB-p-50 
Compared to the control rats, the amount of p-NF-kB-p-50 was 56% and 12% 
higher in the MCT and MCT + CeO2 nanoparticles rats, respectively (Figure 3-12, Panel 
B, P<0.05). Total NF-kB-p-50 was 10% lower in MCT group but only 3% lower with 
CeO2 nanoparticle treatment (Figure 3-12, Panel B, P<0.05). 
 
Effects of CeO2 nanoparticles treatment on serum protein biomarkers 
Compared to control rats, MCT insult appeared to increase the amount of serum 
C-reactive protein (CRP), TNF-α, CD40 Ligand, serum amyloid protein, von Willebrand 
factor, vascular endothelial growth factor A, macrophage inflammatory protein-1 beta, 
macrophage colony-stimulating factor-1, and tissue inhibitor of metalloproteinase-1, 
which appeared to be attenuated with CeO2 nanoparticle treatment (Figure 3-13). 
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CeO2 nanoparticles treatment decreases MCT-induced cardiomyocytes apoptotic 
signaling 
The TdT-mediated dUTP nick end labeling (TUNEL) procedure was used to 
determine the number of cardiomyocytes in the right ventricle that exhibited DNA 
fragmentation. Compared to control rats, MCT insult was associated with an increase in 
the number of TUNEL positive nuclei (Figure 3-14). To extend upon these findings, we 
next examined the effects of treatment on Bax and Bcl-2 expression. Compared to 
control rats, the ratio of Bax/Bcl-2 was 84% higher in the MCT animals but only 29% 
higher in the MCT + CeO2 group (Figure 3-15, Panel A, P<0.05). Similarly, the amount 
of cleaved caspase-3 (19 kDa) was 19% higher in the MCT animals but only 1% higher 
in the MCT + CeO2  rats, respectively (Figure 3-15, Panel B, P<0.05).  
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Discussion 
In spite of recent advances in the early diagnosis and treatment of pulmonary 
arterial hypertension (PAH), right ventricular hypertrophy and failure remain the leading 
cause of death seen with this disease [158]. The monocrotaline model of PAH is 
characterized by elevated pulmonary pressure and increased tissue superoxide levels 
that are associated with the development of right ventricular hypertrophy and failure 
[46]. Previous data has suggested that antioxidant treatment in the rat monocrotaline 
model of PAH can reduce oxidative stress levels and diminish the extent of right 
ventricular remodeling [98, 159]. Supporting this contention, and consistent with 
previous data demonstrating that CeO2 nanoparticles exhibit the ability to function as an 
antioxidant both in vitro and in vivo [15, 110] we demonstrate that CeO2 nanoparticle 
administration diminishes the development of right ventricular (RV) hypertrophy and  
evidence of reduced MAPK, and pro-apoptotic signaling (Table 3-1, Figures 3-2, 3-3, 3-
4, 3-9,3-10,3-11, 3-12 and 3-15). 
  
Effect of CeO2 nanoparticle administration on monocrotaline-induced pulmonary 
hypertension and cardiac remodeling 
Consistent with previous work [60], we observed that monocrotaline insult was 
associated with increased pulmonary arterial pressure and right ventricular hypertrophy 
(Table 3-1, Figures 3-2, 3-3 and 3-4). Specifically, our echocardiography data 
demonstrated that MCT treated rats exhibited an 18% increase in pulmonary arterial 
pressure (Figure 3-3 A), a 27% increase in mean pulmonary arterial diameter (Figure 3-
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3 B), a 46% higher mean pulmonary arterial area (Figure 3-3 C), and a 14% increase in 
right ventricular out flow tract diameter (Figure 3-3 D). More importantly, however, we 
found that CeO2 nanoparticle treatment appeared to attenuate monocrotaline-induced 
changes in pulmonary flow and the development of PAH and PAH associated RV 
hypertrophy (Table 3-1, Figures 3-2, 3-3 and 3-4). These data are consistent with 
previous work showing that CeO2 nanoparticles can protect cultured cardiac myocytes 
from cigarette smoke extract [148] and hydrogen peroxide-induced oxidative damage in 
culture [160].  
 
In the present study, we noted monocrotaline-associated increases in RV tissue 
weight, right ventricular anterior free wall thickness, and ventricular septal diameter was 
diminished with CeO2 nanoparticle treatment (Table 3-1, Figures 3-4, 3-5). In addition, 
our echocardiography analysis suggested the presence of altered atrial and ventricular 
geometry including the bowing of the right atria towards left atria, septal flattening during 
diastole, septal bulging into the LV cavity during systole, and tricuspid regurgitation in 
the monocrotaline treated animals (Figure 3-6) but not in the CeO2 nanoparticle treated 
animals. 
 
In an effort to better characterize the hypertrophic response, we next investigated 
whether monocrotaline induced increases in right ventricular mass were associated with 
cardiomyocyte hypertrophy and fibrosis. To this end, we first measured cardiomyocyte 
cross sectional area (CSA) in each of the three animal groups. Similar to our findings at 
the whole tissue level, our histological studies and quantification of the data 
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demonstrated that CeO2 nanoparticle treatment diminished monocrotaline-induced 
increases in right ventricular cardiomyocyte CSA (Figure 3-7), cardiac fibrosis (Figure 3-
7) and fibronectin protein levels (Figure 3-8 A).  
 
In addition to changes in tissue morphology, cardiac hypertrophy is also 
associated with changes in contractile protein expression. During the hypertrophic 
process, the heart undergoes an up-regulation in the amount of β-MHC and a down-
regulation in the amount of α-MHC [161], which results in an increased efficiency of 
cardiac contraction [162]. In the present study, and similar to previous work [163], we 
found that MCT-induced increases in cardiac mass were associated with increases in β-
MHC expression (Figure 3-8 B) and importantly, that this up-regulation was attenuated 
following CeO2 nanoparticle administration (Figure 3-8 B).  
 
CeO2 nanoparticle administration diminishes indices of oxidative stress during 
pulmonary arterial hypertension 
It has been postulated that increases in oxidative stress may be involved in the 
initiation and progression of cardiac hypertrophy in the MCT-PAH rat model [164, 165]. 
Consistent with previous work demonstrating the antioxidant activity of CeO2 
nanoparticles [106], we found that CeO2 nanoparticle treatment was associated with 
decreased tissue superoxide anion levels (Figure 3-9), diminished tyrosine nitration 
(Figure 3-10 A) and an attenuation in the amount of MCT-induced protein carbonylation 
(Figure 3-10  B). Whether the changes we observe in ROS stress are due entirely to the 
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antioxidant activity of CeO2 nanoparticles or if they may be related to increases in 
antioxidant activity is currently unclear.  
 
Recent work has suggested that AMPK, MAPK, HSP and NF-kB signaling are 
regulated, at least in part, by oxidative stress [166-169] and that antioxidants can 
function to block the activation of these molecules both in vitro and in vivo [170, 171]. 
Other data has demonstrated that these signaling pathways are important regulators of 
ventricular remodeling following pressure overload [170, 172]. Supporting these 
findings, we found that MCT-induced right ventricular hypertrophy was associated with 
increased phosphorylation (activation) of AMPK-alpha, ERK 1/2, JNK-MAPK (Figure 3-
11), HSP-27 and NF-kB p50 (Figure 3-12). The effect of activation was diminished with 
CeO2 nanoparticle treatment (Figure 3-11, 3-12). Whether these alterations in these 
signaling pathways are responsible for the diminished cardiac remodeling we observed 
with CeO2 nanoparticle treatment is currently unclear.  
 
In humans, the involvement of leukocytes and macrophages in the inflammatory 
process leading to the development of PAH associated vascular lesions is well 
documented [173, 174]. It is thought that inflammation plays a significant role in MCT-
induced PAH [175]. We found that MCT administration was associated with the up-
regulation of several serum protein markers associated with inflammation (e.g. C-
reactive protein (CRP), tissue necrosis factor alpha (TNF-α)) and that this up-regulation 
was attenuated following CeO2 nanoparticle administration (Figure 3-13). 
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CeO2 nanoparticle administration diminishes monocrotaline-induced increases in 
apoptosis 
Recent data has suggested that cardiomyocyte apoptosis may be involved in the 
ventricular remodeling seen during MCT-induced PAH [176]. To examine this we 
determined the number of TUNEL positive nuclei in right ventricular tissue sections 
obtained from the control, MCT, and MCT + CeO2 nanoparticle groups. Consistent with 
our present data we found that CeO2 nanoparticle treatment was associated with a 
reduced number of TUNEL positive nuclei (Figure 3-14), diminished Bax/Bcl2 ratio 
(Figure 3-15, Panel A), a decreased caspase-3 cleavage (activation) (Figure 3-15, 
Panel B) which are suggestive of diminished cellular apoptosis.  
 
Taken together, the data of the present study demonstrated that CeO2 
nanoparticle administration attenuates MCT-induced increases in ventricular 
hypertrophy and that this finding is associated with diminished levels of tissue oxidative 
stress and apoptosis. Future experiments designed to directly uncover the 
mechanism(s) of this finding may be warranted.  
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Table 3-1. Cerium oxide nanoparticle treatment attenuates monocrotaline-induced 
increases in right ventricular remodeling. * indicates significant difference from 
control animals, † indicates significant difference from the MCT only group. 
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Figure 3-1.Characterization of CeO2 nanoparticles size.  Nanoparticle size was 
determined by DLS (Panel A) and AFM (Panel B). 
 
 
 
 
61 
 
 
Figure 3-2.CeO2 nanoparticle treatment improves pulmonary flow. Pulsed-wave 
Doppler echocardiography demonstrating normal, round shaped flow profile on day 1 
(base line) of MCT rats (Panel A),  triangular flow profile with mid systolic notching on 
day 28 of MCT rats progression to pulmonary arterial hypertension (Panel B) (arrow), - 
normal, round shaped flow profile on day 1 (base line) of MCT + CeO2 nanoparticle 
treated rats (Panel C), - attenuation of pulmonary arterial hypertension and restoring the 
normal, round shaped flow profile as of baseline observed with CeO2 nanoparticle 
treatment (Panel D). 
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Figure 3-3.CeO2 nanoparticle administration diminishes pulmonary artery 
remodeling. Pulsed-wave Doppler echocardiography quantified data form Pulmonary 
arterial pressure (Panel A), mean pulmonary arterial diameter (Panel B), mean 
pulmonary arterial area (Panel C), right ventricular outflow tract diameter (Panel D). 
Data are mean ± SEM (n= 6 rats/group). In the graphs, Grey bars represent base line 
and black bars represent final echocardiographic values. * indicates significant 
difference from base line values of MCT only group and † indicates significant 
difference from final values of MCT only group (p<0.05). 
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Figure 3-4.CeO2 nanoparticle treatment attenuates MCT-induced increases in right 
ventricle wall thickness. M-mode echocardiography images representing right 
ventricle wall thickness of the MCT only rats on day 1 (Panel A) and at day 28 (Panel B) 
or the MCT + CeO2 nanoparticle treated rats on day 1 (Panel C) and at day 28 (Panel 
D).  The larger arrow in Panel B represents the increases in RV anterior wall thickness. 
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Figure 3-5.CeO2 nanoparticle treatment attenuates MCT-induced cardiac 
remodeling. Ventricle wall thickness (Panel A) and intra-ventricular septum diameter 
(Panel B) in the MCT only and MCT treated animals. Data are mean ± SEM, (n= 6 
rats/group). In the graphs, grey bars represent the base line and black bars represent 
the final echocardiography values. * indicates significant difference from base line 
values of MCT only group and † indicates significant difference from final values of MCT 
only group (p<0.05). 
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Figure 3-6.PAH associated changes in cardiac function in the MCT only animals. 
Short-axis view of transthorasic echocardiogram showing right atrium bowing towards 
the left atrium (Panel A). Dilatation of the RV with septal flattening of the interventricular 
septum causing the left ventricle to conform into a “D” shape (Panel B). Tricuspid 
regurgitation (Panel C). 
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Figure 3-7.CeO2 nanoparticle administration attenuates monocrotaline-induced 
increases in cardiomyocyte cross sectional area and cardiac fibrosis. Dystrophin 
stained right ventricular sections from control (Panel A), MCT only (Panel B), and MCT 
+ CeO2 nanoparticle treatment animals (Panel C). Quantification of cardiomyocyte 
cross-sectional area (Panel D). Picrosirius red staining was used to evaluate cardiac 
fibrosis in the right ventricles of control (Panel E), MCT only (Panel F) and MCT + CeO2 
nanoparticle treatment animals (Panel G). Scale bar 50μm. Data are mean ± SEM (n = 
3 rats/group). For each group 9 sections were analyzed.  * indicates significant 
difference from the control and † indicates significantly different from the MCT only 
group (p<0.05).  
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Figure 3-8.MCT induced increases in RV fibronectin and MHC-beta are attenuated 
with cerium oxide nanoparticle treatment. Protein isolates from the right ventricle of 
control, MCT only, MCT + CeO2 nanoparticle treated rats were analyzed by 
immunoblotting for changes in fibronectin (Panel A) and myosin heavy chain-beta 
(Panel B) protein levels. Protein abundance was normalized to the expression of 
GAPDH. n=6 for each group. * indicates significant difference from the control and † 
indicates significantly different from the MCT only group (p<0.05).  
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Figure 3-9.CeO2 nanoparticle treatment decreases the incidence of superoxide 
levels in MCT-induced RV hypertrophy. Cardiac ROS determined by fluorescence 
intensity of ethidium bromide – stained nuclei. * Significantly different from control rats, 
† Significantly different from the MCT only rats (P<0.05).  
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Figure 3-10.Cerium oxide nanoparticle treatment decreases MCT-induced 
increases in protein nitration and carbonylation. Protein isolates obtained from the 
right ventricles of control, MCT only and MCT + CeO2 nanoparticle treated rats were 
analyzed by immunoblotting for alterations in protein nitrosylation (Panel A) and 
carbonylation (Panel B). * Significantly different from control rats, † Significantly different 
from the MCT only rats (P<0.05). n= 6 animals / group 
  
70 
 
 
 
 
Figure 3-11.Cerium oxide nanoparticle treatment decreases the MCT-induced 
increases in AMPK-alpha, ERK1/2 and JNK phosphorylation. Protein isolates 
obtained from the right ventricles of control, MCT only and MCT + CeO2 nanoparticle 
treated rats were analyzed by immunoblotting to determine the phosphorylation of 
AMPK-alpha (Panel A), ERK1/2 (Panel B) and JNK (Panel C). * Significantly different 
from control rats, † Significantly different from the MCT only rats (P<0.05). n= 6 animals 
/ group. 
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Figure 3-12. Cerium oxide nanoparticle treatment decreases the MCT induced 
oxidative stress associated phosphorylation of HSP-27 and NF-kB p50. Protein 
isolates of RV from control, MCT only and MCT + CeO2 nanoparticle treated rats were 
analyzed by immunoblotting to determine alterations in HSP-27(Panel A) and NF-kB 
regulation (Panel B). * Significantly different from control rats, † Significantly different 
from the MCT only rats (P<0.05).n = 6 animals / groups. 
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Figure 3-13. Alterations in serum protein biomarkers with MCT and MCT + CeO2 
nanoparticle treatment. 
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Figure 3-14.CeO2 nanoparticles treatment decreases the incidence of TUNEL 
positive nuclei in MCT induced RV hypertrophy. Immunofluoresence labeling of 
TUNEL positive nuclei (FITC) in control (Panel A), MCT only (Panel B), MCT + CeO2 
nanoparticle treated animals (Panel C). Bar 50 μm. n = 3 animals / group. 
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Figure 3-15.Cerium oxide nanoparticle treatment is associated with diminished 
pro-apoptotic signaling. Protein isolates obtained from the right ventricles of control, 
MCT only and MCT + CeO2 nanoparticle treated rats were analyzed by immunoblotting 
to determine the Bax/Bcl-2 protein levels (Panel A) and caspase-3 cleavage (Panel 
B).*Significantly different from control rats,  †Significantly different from the MCT only 
rats (P<0.05). n = 6 animals / group. 
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PAPER 3 
The following paper corresponds to the specific aim II 
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Curcumin nanoparticles attenuate cardiac remodeling due to pulmonary arterial 
hypertension 
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Effect of curcumin nanoparticles on cardiac hypertrophy following pulmonary arterial 
hypertension. 
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Abstract 
Introduction: Pulmonary arterial hypertension (PAH) is a progressive disorder that can 
cause right ventricular failure and death. Curcumin is a polyphenol compound that 
exhibits anti-inflammatory and antioxidant properties whose clinical application has 
been hindered by poor solubility, short biological half-life, and low bioavailability after 
oral administration. Herein, we investigate whether curcumin nanoparticles (Cur NP) are 
effective for the treatment of monocrotaline (MCT)-induced PAH in the laboratory rat. 
Methods: Cur NP was prepared using an emulsion-diffusion-evaporation technique. 
Male Sprague Dawley rats (175-200 gm) were randomized into control, MCT only or 
MCT + Cur NP groups (n=6 each / group). PAH was induced by a single subcutaneous 
injection of MCT (60 mg/kg). MCT + Cur NP treated rats received 50 mg/kg of Cur NP in 
0.5 ml of distilled water i.p. daily for seven days while the control and MCT groups 
received only distilled water. Echocardiography was done at the start of the study and 
twenty eight days after MCT injection. Results: Compared to MCT only animals, Cur 
NP administration was associated with diminished pulmonary arterial pressure (71 ± 2 
vs. 67 ± 2 mmHg, P<0.05), reduced right ventricular wall thickness (0.27 ± 0.02 cm vs. 
0.23 ± 0.01 cm,) and a decreased right ventricle weight/body weight ratio (0.74 ± 0.06 
vs. 0.57 ± 0.02 mg/gm, P<0.05). MCT insult elevated the serum TNF-α levels (19%) 
which were reduced with Cur NP treatment. Cur NP treatment attenuated cardiac 
fibrosis and the development of RV hypertrophy. Conclusions: Taken together, these 
data suggest that Cur NP may attenuate MCT-induced pulmonary arterial hypertension 
and right ventricle hypertrophy. WC: (261) 
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Introduction 
Pulmonary arterial hypertension (PAH) is a debilitating disease characterized by 
progressive obstruction of the pulmonary arteries which can cause a rise in pulmonary 
vascular resistance (PVR) and right ventricular (RV) hypertrophy [177]. The median 
survival rate in PAH patients without treatment is 2.8 years after diagnosis and the 
estimated survival rates at 1-, 3- and,5-years is 68%, 48% and 34%, respectively [178]. 
Not unexpectedly, RV failure is the most common cause of death in PAH patients (~ 30-
50% of deaths) [179]. Current therapeutic treatments, although effective in improving 
symptomology, only delay disease progression. As of yet, a cure for PAH has not been 
found and long term survival remains poor [180]. 
   
Curcumin (diferuloylmethane) is a polyphenolic compound in the curry spice 
turmeric that has been used in Indian Ayurvedic medicine for the treatment of 
inflammatory diseases [181]. Recent data has shown that curcumin exhibits anti-
inflammatory, anti-oxidant and anti-proliferative activity [28], most likely through its 
ability to scavenge free radicals, diminish cytokine expression (e.g, tumor necrosis 
factor (TNF)- α, interleukin (IL)-1, and IL-6) and inhibit the activity of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB) [182, 183]. Curcumin has been 
used to improve left ventricular function in rabbits subjected to pressure-overload [184] 
and inhibit cardiac inflammation and fibrosis in rats [35]. 
 
Thus far, the biomedical application of curcumin has been hampered due to its 
poor water solubility and short biological half-life [38]. Recent studies, using 
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nanoparticle-based systems, have shown increased curcumin bioavailability [39, 137]. 
Here, we examine whether the systemic administration of curcumin nanoparticles (Cur 
NP) can diminish PAH-induced cardiac hypertrophy in the rat. To induce PAH, rats were 
subjected to a single subcutaneous injection of monocrotaline (MCT; 60 mg/kg). MCT is 
a macrocylic pyrrolizidine alkaloid that when metabolized by cytochrome P450 
(CYP3A4) is converted to dehydromonocrotaline, which selectively injuries the vascular 
endothelium of lung causing an increase in pulmonary arterial pressure [185]. Given the 
pivotal role that inflammation plays in the development of PAH [10], we hypothesized 
that Cur NP treatment would diminish the expression of inflammatory mediators and 
that this reduction in inflammation would be associated with decreased right ventricular 
hypertrophy. 
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Materials and Methods 
PAH model and experimental design 
All procedures were approved by the Institutional Animal Care Committee of 
Marshall University using the criteria outlined by the American Association of Laboratory 
Animal Care (AALAC). Male Sprague Dawley rats (7 weeks old, 175-200 gm) were 
obtained from Hilltop laboratories (Scottsdale, PA) and were housed two per cage in an 
AALAC approved vivarium at Marshall University. The animal housing facility was 
operated with a 12 hour: 12 hour dark – light cycle and maintained at 22 ± 2°C. Rats 
were provided with food and water ad libitum and allowed to acclimate to the housing 
facilities for at least two weeks before experimentation. Animals were randomly 
assigned to one of three experimental groups 1.) Control (n=6), 2.) MCT only (n=6), or 
3.) MCT + Cur NP treatment (n=6). PAH was induced by a single injection of MCT (60 
mg/kg s.c.) (Sigma-Aldrich, St.Louis, MO) as described previously [149]. Animals 
injected with MCT were given either Cur NP (50 mg/kg i.p.) or vehicle (DI water) once 
daily for seven days following the MCT injection.  
 
Preparation of curcumin nanoparticles 
Curcumin (100 mg) was solubilized in dichloromethane (10 ml), and 1 ml of this 
solution was sprayed into deionized water (25 ml) drop wise at a flow rate of 0.2 ml/min 
in 5 min under ultrasonic conditions, with an ultrasonic power of 100 W and a frequency 
of 30 kHz. After sonication for 10 min, the contents were stirred at 400-800 rpm at room 
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temperature for about 30 min until a clear orange-colored solution was obtained. The 
solution was concentrated under reduced pressure at 50°C and then dried at 40°C to 
obtain an orange powder. 
 
Scanning Electron Microscopy   
 Curcumin nanoparticles’ size and morphology were characterized using scanning 
electron microscope (SEM) (JEOL’s JSM 7400 SEM). The SEM was operated at 5 kv. 
The samples were prepared by fixing the curcumin nanoparticles to a microscope 
holder using a conducting carbon strip. 
 
Atomic Force Microscopy 
Curcumin nanoparticles (1µg/µl) were deposited on freshly cleaved mica (V1 
mica, SPI Inc, West Chester, PA). After a 10 min incubation period, the surface was 
gently rinsed with deionized (DI) water to remove any unbound nanoparticles and the 
sample was dried under nitrogen. Particles were imaged in noncontact mode at a  319 
kHz with a scan speed 0.5 Hz using a Nano-R microscope (Pacific Nanotechnology, 
Santa Clara, CA) equipped with a TM300-A probe (Sensa Probes Inc, Santa Clara, 
CA.). 
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Echocardiography 
Echocardiography was performed using a Philips 5500 ultrasound machine with 
an S-12 transducer frequency at the beginning of the study and at 4 weeks to assess 
pulmonary and right ventricular structure and function as outlined previously [186]. 
Briefly, rats were anesthetized with an intraperitoneal injection of ketamine and xylazine 
(4:1, 50 mg/kg). Once anesthetized, the ventral thorax area was shaved and covered 
with ultrasonic transmission gel. Electrocardiograms were recorded simultaneously to 
monitor heart rate. Echocardiography images were obtained in the 2-dimensional 
guided M-mode and Doppler M-mode from parasternal long-axis (PLAX) and 
parasternal short-axis (PSAX) views. M-mode measurements of the RV, LV and wall 
thickness were performed from PSAX image plane. Pulmonary artery flow was 
measured at the pulmonary valve level and pulmonary artery diameter was measured at 
the level of pulmonary out flow tract during systole using the PSAX view. An apical four-
chamber view was employed to measure end-diastolic right ventricular area. Pulsed-
wave Doppler was used to measure pulmonary artery acceleration time and flow. 
Measurements from six rats in each group were obtained for the assessment of cardiac 
structure and function. 
 
Tissue processing and immunoblotting 
RV cardiac muscles were pulverized in liquid nitrogen using a mortar and pestle 
until a fine powder was obtained and homogenized in TPER lysis buffer (Pierce, 
Rockford, IL) containing protease (P8340, Sigma-Aldrich, Inc., St. Louis, MO) and 
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phosphatase inhibitors (P5726, Sigma-Aldrich, Inc., St. Louis, MO). After incubation on 
ice for 30 min, the homogenate was collected by centrifuging at 12,000 g for 5 min at 
4°C. The protein concentration of homogenates was determined in triplicate via the 
Bradford method (Fisher Scientific, Rockford, IL). Homogenate samples were boiled in a 
Laemmli 2X sample buffer (Sigma-Aldrich, Inc., St. Louis, MO) for 5 min before loading 
forty micrograms of total protein from each sample on 10% PAGEr Gold Precast gels 
(Lonza, Rockland, ME). Proteins were transferred onto nitrocellulose membranes using 
standard conditions [187]. For immunodetection, membranes were blocked for 1 h at 
room temperature in blocking buffer (5% non-fat dry milk in TBS-T (20mM Tris-base, 
150mM NaCl, 0.05% Tween-20), pH 7.6), serially washed in TBS-T at room 
temperature, then probed with primary antibodies for the detection of β-myosin heavy 
chain (M 8421, Sigma Aldrich, St. Louis, MO), fibronectin (AB23750, Abcam, 
Cambridge, MA), p-AMPK-α (#2535), AMPK-α (#2532),  HSP-27 (#2442s), HSP-70 
(#4872), Bax (#2772), Bcl2 (#2870s), Caspase-3 (#9662), cleaved caspase-3 (#9661s), 
caspase-9 (#9506), ERK1/2 (#9106s), p-ERK1/2 (#4377s), p-p-38 (#9216L), p-38 
(#9212), p-JNK (#9251s), JNK (#9252), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (#2118), (from Cell Signaling Technology, Inc., Beverly, MA) and 3-
nitrotyrosine (SC-55256) (from Santa Cruz Biotechnology, Inc., Santa Cruz, CA). 
Membranes were incubated overnight at 4°C in primary antibody buffer (5% BSA in 
TBS-T, pH 7.6, primary antibody diluted 1:1,000), followed by washing in TBS-T (3 x 5 
min), and incubation with HRP-conjugated secondary antibody (anti-rabbit ((#7074)) or 
anti-mouse ((#7076)), Cell Signaling Technology, Inc., Danvers, MA) in blocking buffer 
for 1 h. After removal of the secondary antibody, membranes were washed (3 x 5 min) 
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in TBS-T and protein bands were visualized following reaction with ECL reagent 
(Amersham ECL Western Blotting reagent RPN 2106, GE Healthcare Bio-Sciences 
Corp., NJ). Target protein levels were quantified by AlphaView SA image analysis 
software (Alpha InfoTech, San Leandro, CA) and normalized to GAPDH. 
 
Histology 
Picrosirius red staining was used to assess the collagen content deposition in the 
right ventricle  as detailed elsewhere [188]. Briefly, frozen tissue sections were fixed 
with 95% alcohol for 1 min, washed three times with running tap water, and then stained 
with hematoxylin for 8 min and picrosirius red for 20 min. After dehydration, sections 
were mounted and visualized at 20x or 40x magnification using an Olympus BX51 
microscope (Olympus, Center Valley, PA). 
 
Determination of cytokine levels in serum by ELISA method 
Serum concentrations of tumor necrosis factor (TNF)-α and interleukin-1β  (IL-
1β) were measured using commercially available enzyme-linked immunosorbent assay 
(ELISA) kits (BD Bioscience, San Diego, CA) according to the manufacturer’s 
instructions [24]. Absorbance measurements for each plate were taken at 450 nm using 
ELISA plate reader (BioTek, Winooski, Vermont). 
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Determination of cardiac TNF-α and IL-1βmRNA levels 
RV tissue was homogenized in TRI reagent (Ambion, Austin, TX) at a 
concentration of 1ml for every 100mg of tissue as detailed elsewhere [189]. Briefly, after 
5 minutes of incubation with TRI reagent, the homogenates were centrifuged (12,000 g 
for 15 min at 4 °C). The supernatant was collected and mixed with 200 μl of chloroform 
(Sigma-Aldrich, Inc., St. Louis, MO). After a 10 min incubation at room temperature, the 
aqueous phase of the mixed solution was collected via centrifugation (12,000 g for 15 
min at 4 °C) and then mixed with 500 μl of isopropanol  (Sigma-Aldrich, Inc., St. Louis, 
MO). RNA pellets were precipitated (12,000 x g for 10 min at 4 °C), washed with 75% 
ethanol, and then dried under vacuum to remove residual ethanol. RNA pellets were 
dissolved in 50 μl of 10mM Tris, pH8.0 and 1mM EDTA. RNA was quantified at 260 nm 
using a NanoVue UV-Vis Spectrophotometer (GE Healthcare, Piscataway, NJ), and 
RNA integrity was confirmed using a RNA Nanokit and Agilent 2100 Bio-analyzer 
(Agilent Technologies, Santa Clara, CA). RNA samples were stored at -80°C until 
further use. 
  
Reverse transcription coupled with RT-PCR was used to quantify the relative 
abundance of TNF-α and IL-1β mRNA levels in control, MCT and MCT + Cur NP 
animals. Complementary DNA (cDNA) libraries were synthesized using a High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems Inc., Foster City, CA) as detailed 
elsewhere [189]. 
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 RT-PCR was performed using the Power SYBER Green PCR Master Mix 
(Applied Biosystems Inc., Foster City, CA) as outlined previously [190]. PCR reactions 
were run on an ABI 7000 Real-Time PCR system (Applied Biosystems Inc., Foster City, 
CA) using the following cycle conditions: 50°C for 2min, 95°C for 10min, followed by 40 
cycles at 95°C for 15s and 60°C for 1min as detailed elsewhere [191]. All experiments 
were repeated in triplicate. β-actin or glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) were used as internal controls. The forward and reverse primers were 
purchased from Integrated DNA technologies (San Diego, CA). TNF-α Gene bank 
accession number: NM_012675.3 with forward primer (5'-3') - 
CCAGAACTCCAGGCGGTGTC, reverse primer (5'-3')-GGCTACGGGCTTGTCACTCG, 
IL-1β Gene bank accession number: NM_031512.2 forward primer (5'-3') - 
TGCCCGTGGAGCTTCCAGGA, reverse primer (5'-3')-TCCAGCTGCAGGGTGGGTGT. 
The expression of TNF-α and IL-1β mRNA levels were normalized to the geometric 
means of β-actin and GAPDH mRNA levels, and the 2-Δct method was used to calculate 
the relative mRNA expression levels. 
 
Data analysis 
Results are presented as mean ± SEM. Data were analyzed using SigmaPlot 
11.0 software. One-way analysis of variance (ANOVA) was used for overall 
comparisons.  The Student Newman Keuls post hoc test was used where appropriate to 
determine differences between groups. The level of significance accepted a priori was P 
≤ 0.05. 
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Results 
Curcumin NP characterization 
 The particle size analysis of the nanoparticles was performed by scanning 
electron microscope (SEM) and atomic force microscope (AFM). The SEM of powdered 
sample showed the particle size to be in the range of 300 ± 50 nm (Figure 3-16 A, B) 
and AFM of aqueous dispersion showed the particles to be approximately 50 nm in size 
(Figure 3-16  C).    
 
Curcumin NP treatment decreases PAH induced right ventricular tissue weight 
Compared to control animals, body weight was 19% less in the MCT and MCT + 
Cur NP rats, respectively (P<0.05) (Table 3-3). Conversely, the ratio of right ventricle 
(RV) weight to body weight ratio was 27% and 10% higher in the MCT and MCT + Cur 
NP animals (P<0.05). Similarly, the lung weight to body weight ratio was 356% and 
214% higher in the MCT and MCT + Cur NP groups, respectively (P<0.05). 
 
Curcumin NP treatment decreases MCT-induced changes in pulmonary arterial 
pressure and cardiac remodeling 
Compared to the MCT + Cur NP animals, echocardiographic analysis of 
pulmonary arterial flow demonstrated a mid-systolic notch in the MCT animals (Figure 
3-17, Panels A-D). Consistent with this finding, pulmonary arterial pressure (PA Pr) was 
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18% and 10% higher in the MCT and MCT + Cur NP animals, respectively (Figure 3-17 
E, P<0.05). Likewise, the slope of the pulmonary artery acceleration vector was 200% 
and 52% in higher in the MCT and MCT+ Cur NP animals, respectively (Figure 3-17 F, 
P<0.05). Similar to our findings at the whole tissue level, echocardiography analysis 
demonstrated that Cur NP treatment attenuated MCT-induced increases in RV anterior 
free wall thickness (Figure 3-18).  
 
To examine the molecular changes that might accompany PAH-induced changes 
in RV thickness we next performed immunoblotting to examine myosin heavy chain 
expression. Compared to the control animals, MHC-β expression was 278% and 106% 
higher in the MCT and MCT + Cur NP treated animals, respectively (Figure 3-19 A, 
P<0.05). Similarly, picrosirius red staining of the right ventricle suggested that the 
degree of MCT-induced collagen deposition was less in the Cur NP treated animals 
when compared to that in the MCT only treated animals (Figure 3-19, Panel B, C and 
D). In an effort to extend these findings, we next examined the effect of Cur NP 
treatment on fibronectin expression with MCT treatment. Compared to that observed in 
the control animals, fibronectin protein levels were 95% and 57% higher in the MCT and 
Cur NP MCT animals, respectively (Figure 3-19, Panel E, P<0.05).  
 
Curcumin nanoparticle treatment decreases serum TNF-α levels 
Compared to the control animals, serum TNF-α levels were 19% and 5% higher 
in the MCT and MCT + Cur NP animals, respectively (Figure 3-20, Panel A, P<0.05). 
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The amount of serum IL-1βwas not changed in the MCT or MCT + Cur NP animals 
(data not shown). At the tissue level, the abundance of TNF-α level was 124% and 2% 
higher in the  MCT and MCT + Cur NP animals, respectively (Figure 3-20, Panel B, 
P<0.05) and IL-1β message level was 227% higher and 7% lower in the  MCT and MCT 
+ Cur NP animals, respectively (Figure 3-20, Panel C, P<0.05). 
 
Curcumin nanoparticle treatment decreases AMPK alpha phosphorylation but not 
MAPK or apoptotic signaling 
Compared to the control animals, the amount of p-AMPK alpha was decreased 
by 36% and 22% in the MCT and MCT + Cur NP animals, respectively (P<0.05) (Figure 
3-21). No differences in the ratio of Bax/Bcl-2, the amount of cleaved caspase-3, p-
ERK1/2, p-p38, or p-JNK1/2 was observed with nanoparticle treatment.  
 
Curcumin nanoparticle treatment decreases MCT-induced increases in oxidative 
stress signaling 
Compared to the control animals, the amount of HSP 27was 25% and 15% 
higher in the MCT and MCT + Cur NP animals (Figure 7, Panel A, P<0.05). Like that 
observed for HSP 27, HSP70 protein levels were 42% and 22% higher in the MCT and 
MCT + Cur NP animals (Figure 3-22, Panel B, P<0.05). Likewise, 3-nitrotyrosine protein 
was 23% higher in the MCT animals and 11% higher in the MCT + Cur NP animals 
(Figure 3-22, Panel C, P<0.05).  
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Discussion 
Recent studies have suggested that curcumin may be effective for the treatment 
of neurodegenerative, pulmonary, autoimmune, and neoplastic diseases [28]. In 
addition, other data have demonstrated that curcumin is able to prevent cardiac 
hypertrophy and heart failure in a murine model of salt-induced hypertension [35]. In an 
effort to extend these findings, the present study investigated whether treatment with 
curcumin nanoparticles was able to attenuate the development of monocrotaline-
induced RV hypertrophy following pulmonary arterial hypertension. Herein, we 
demonstrate that the administration of curcumin nanoparticles (50 mg/kg /i.p.) for seven 
days is capable of diminishing the development of pulmonary arterial pressure and right 
ventricular remodeling in the rat MCT model of pulmonary arterial hypertension (Figures 
3-17, 3-18, and 3-19). These changes appear to be associated with decreased serum 
TNF-α levels and evidence of diminished hypertrophic signaling and oxidative stress in 
the heart (Figures 3-20, 3-21, and 3-22). Taken together, these results are consistent 
with the possibility that curcumin nanoparticle treatment may be efficacious for the 
treatment of pulmonary arterial hypertension.  
 
The most commonly used animal model of PAH utilizes monocrotaline to 
selectively injure the pulmonary vasculature, which causes an increase in pulmonary 
vascular resistance [70, 192]. Similar to the previous reports [186, 193], our 
echocardiography data demonstrated that MCT insult resulted in the obstruction to 
pulmonary arterial flow and increases in pulmonary artery pressure (Figure 3-17). These 
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changes in vascular function pressure, in turn, are associated with increased right 
ventricular mass and free wall thickness (Table 3-3, Figure 3-18). 
 
In an effort to better understand the nature of RV hypertrophy we next examined 
if MCT insult was associated with changes in contractile protein expression and an 
increase in non-contractile tissue. Consistent with previous data [161, 194], we found 
that MCT-insult was associated with an increase in the amount of slow β-myosin heavy 
chain (MHC) isoform, tissue fibrosis and fibronectin protein expression in the pressure 
overloaded right ventricle (Figure 3-19, Panels A, B, C). Importantly, we found that the 
administration of Cur NP was associated with evidence of diminished cardiac 
hypertrophy and tissue fibrosis (Table 3-3, Figures 3-18 and 3-19).  
 
How Cur NP administration may function to diminish cardiac hypertrophy and the 
development of fibrosis is currently unclear. Previous reports have suggested that 
curcumin can act as an anti-fibrotic agent and that the chronic administration of 
curcumin can attenuate the development of pulmonary fibrosis in the rat. It has been 
hypothesized that this effect may be related to the ability of curcumin to reduce 
inflammation [33]. Consistent with this possibility, and the work of others using bulk 
curcumin preparations [195], we found that Cur NP associated decreases in cardiac 
fibrosis were associated with diminished serum TNF-α protein and decreased 
ventricular TNF-α mRNA expression (Figure 3-20, Panels A, B). Whether these 
changes in TNF-α regulation are directly responsible for the changes we see in cardiac 
remodeling is unknown and will require further experimentation.  
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The molecular events that govern the development of cardiac hypertrophy are 
not entirely clear. Recent data has suggested that the phosphorylation (activation) of α-
AMPK functions to inhibit cardiac hypertrophy following chronic pressure overload [196]. 
Supporting this contention, we observed that MCT-induced cardiac hypertrophy was 
associated with decreases in α-AMPK phosphorylation (Figure 3-21). As expected from 
our analysis of cardiac hypertrophy at the tissue level, we noted that Cur NP 
administration appeared to up-regulate α-AMPK phosphorylation (Figure 3-21 Panel A). 
Whether this up-regulation of α-AMPK phosphorylation is related to decreases in 
cellular inflammation or changes in TNF-α expression is unknown and will require 
further experimentation.  
 
It has been reported that the increases in tissue inflammation/oxidative stress 
seen during pressure-overload induced RV hypertrophy can cause an up-regulation in 
heat shock protein expression [197, 198]. Supporting this contention, we observed that 
PAH induced cardiac hypertrophy was associated with increased expression of HSP-27 
and HSP-70 in the right ventricle (Figure 3-22). Consistent with our hypertrophy data, 
we also noted that Cur NP administration was associated with a down-regulation of the 
expression of HSP-27 (Figure 3-22 Panel A) and HSP-70 (Figure 3-22 Panel B) and 
decreased levels of oxidative stress. In addition to increases in HSP expression, 
pressure overload has also been shown to increase tissue oxidative stress [199]. 
Similar to our HSP data, we found that MCT-insult caused an elevation in 3-nitrotyrosine 
levels and that 3-nitrotyrosine levels were diminished with Cur NP administration (Figure 
3-22 Panel C). These data are consistent with the previous work of others showing that 
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curcumin treatment prevented diabetes-induced increases in retinal nitro tyrosine levels 
[200]. 
 
In conclusion, the data of the present study demonstrate that Cur NP treatment 
can attenuate the development of RV hypertrophy in the rat MCT model of PAH. 
Although the exact mechanism of action is not clear, our data suggest that the 
attenuated hypertrophy we observe following Cur NP administration  may be related to 
decreases in TNF-α levels, the activation of α-AMPK, and diminished oxidative stress. 
Although prior work studies have reported that curcumin administration can prevent 
cardiac remodeling it should be noted that the curcumin levels used in this study were 
much higher (150mg/kg/day for 7 weeks) than those used in the present study [201]. 
Whether Cur NP treatment is effective in preventing other types of cardiac hypertrophy 
will require additional study.  
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Table 3-2. Body and organ weight for control, MCT only and MCT + Cur NP rats 
collected 4 weeks after injection of MCT (60mg/kg). Values are expressed as mean 
± SEM; n=6 for each group. * P<0.05 significantly different from control rats and † 
P<0.05 significantly different from MCT only rats. 
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Figure 3-16.Optical characterization of curcumin nanoparticles. Curcumin 
nanoparticles were observed under SEM (Panels A, B) and AFM imaging (Panel C). 
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Figure 3-17.Curcumin nanoparticle treatment improves MCT-induced decreases 
in pulmonary artery flow. Representative image from a MCT only animal at day 1 
(Panel A) and at day 28 (Panel B). Note mid-systolic notch at day 28 (arrow). Images 
from a MCT + Cur NP treated animal at day 1 (Panel C) and at day 28 (Panel D). 
Curcumin nanoparticle treatment decreases MCT-induced increases in pulmonary 
artery flow acceleration (Panel E) and increases the slope of the pulmonary artery 
acceleration vector (Panel F). Values are expressed as mean ± SEM; n=6 for each 
group. * P<0.05 vs. the control group; † P<0.05 vs. the MCT + Cur NP group. 
97 
 
 
 
Figure 3-18.Curcumin nanoparticle treatment attenuates PAH induced increases 
in RV anterior free wall thickness. M-mode echocardiography images of a MCT only 
animal at day 1 (Panel A), and at day 28 (Panel B). Images from a MCT + Cur NP 
treated animal at day 1 (Panel C) and at day 28 (Panel D).Quantification of Doppler 
echocardiography (Panel E). Values are expressed as mean ± SEM; n=6 for each 
group. * P<0.05 vs. the base line of MCT only group; 
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Figure 3-19.Curcumin nanoparticle treatment decreases PAH-induced cardiac 
remodeling. Myosin heavy chain-β abundance in the RV as determined by 
immunoblotting and normalized to the amount of GAPDH (Panel A). Picrosirius red 
staining of right ventricular tissue from control (Panel B), MCT only (Panel C) and MCT 
+ Cur NP treated animals (Panel D). Fibronectin protein abundance normalized to the 
expression of GAPDH (Panel E). Scale bar 50 μm. Graphical data are expressed as 
mean ± SEM; n=6 for each group. * P<0.05 vs. the control group; † P<0.05 vs. the MCT 
+ Cur NP group.  
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Figure 3-20. Curcumin nanoparticle treatment diminished MCT-induced increases 
in inflammatory cytokines. Serum protein TNF-α levels (Panel A).Right ventricular 
mRNA expression levels of TNF-α (Panel B) and IL-1β (Panel C). Values are expressed 
as mean ± SEM; n=5 for each group. * P<0.05 vs. the control group; † P<0.05 vs. the 
MCT + Cur NP group.  
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Figure 3-21. Curcumin nanoparticle treatment alters AMPK-α activation but does 
not change MAPK or apoptotic signaling. Protein expression was determined in RV 
tissue by immunoblotting and normalized to the expression of GAPDH. Values are 
expressed as mean ± SE; n=6 for each group. * P<0.05 vs. the control group; † P<0.05 
vs. the MCT + Cur NP group.  
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Figure 3-22.Curcumin nanoparticle treatment attenuates PAH-associated 
increases in heat shock protein and protein nitrosylation. The abundance 
expression of Hsp-27 (Panel A), Hsp-70 (Panel B) and nitro tyrosine (Panel C) were 
determined by immunoblotting and normalized to the expression of GAPDH. Values are 
expressed as mean ± SEM; n=6 for each group. * P<0.05 vs. the control group; † 
P<0.05 vs. the MCT + Cur NP group.  
 
  
102 
 
CHAPTER IV 
GENERAL DISCUSSION 
 Pulmonary arterial hypertension (PAH) affects almost 15-52 people per million 
people [202]. As of yet, no cure for PAH has been found and the long term survival 
remains poor. Even with modern medical therapy, most of the patients experience 
progression of their disease and many are referred for lung transplantation [5]. Right 
ventricular failure is the leading cause of death in patients with PAH. The exact 
molecular mechanisms underlying the structural and functional alterations that lead to 
the RV dysfunction are not well understood. Although animal models lack the 
development of the classical plexiform lesions seen in human PAH, it is thought that the 
rat monocrotaline injury is useful for studying the pathological processes seen in human 
PAH.  
 
Recent data suggests that  increases in pulmonary artery resistance are the main 
causative agent in the development of PAH-induced RV hypertrophy and RV 
dysfunction [203]. In addition to increased mechanical loading, other data has 
demonstrated that the development of right heart failure may also be mediated, at least 
in part, by increases in reactive oxygen species and inflammatory mediators [9]. 
 
The primary purpose of this study was to determine the efficacy of CeO2 and 
curcumin nanoparticles to attenuate monocrotaline-induced PAH and RV hypertrophy. 
To accomplish this goal, we examined the effects of nanoparticle administration on 
pulmonary artery pressure/flow, RV thickness as determined by echocardiography, RV 
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mass, RV fibrosis, myocyte cross sectional area, and indices of oxidative stress and 
myocardial apoptosis. 
 
Effects of CeO2 nanoparticle administration on monocrotaline-induced RV 
hypertrophy in Sprague-Dawley rats 
 Previous study has shown that CeO2nanoparticles exhibit antioxidant activity 
both in vitro and in vivo [106]. Other data has shown that CeO2 nanoparticles may also 
exhibit catalytic activities similar to superoxide dismutase and catalase [109]. Recent 
work has shown that the administration of CeO2 nanoparticles can inhibit left ventricular 
dysfunction and myocardial oxidative stress in the MCP-1 transgenic mouse model of 
cardiomyopathy [23]. Similarly, Kong and coworkers demonstrated that CeO2 
nanoparticles could inhibit retinal degeneration in tubby mice and that this finding was 
associated with diminished oxidative stress and a down-regulation of apoptotic signaling 
[109]. 
  
Here, we observed that that CeO2 nanoparticle administration is capable of 
preventing monocrotaline-induced PAH and RV hypertrophy in male Sprague Dawley 
rats (Chapter 3, Paper #1). Specifically, our echocardiography and histological data 
demonstrate that CeO2 nanoparticle administration was associated with a lower RV 
weight to body weight ratio, decreased cardiomyocyte fiber cross sectional area, and 
diminished RV myocardial fibrosis.  
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Other data from this study suggest that CeO2 nanoparticle treatment is able to 
diminish monocrotaline-induced increases in cellular ROS and cardiomyocyte apoptosis 
(Chapter 3, Paper #1). Specifically, we observed that CeO2 nanoparticle administration 
was associated with decreases in superoxide anion, diminished protein nitrosylation, an 
attenuation in apoptotic signaling ( Bax/Bcl2 ratio and caspase-3 cleavage), reduced 
activation of stress-associated signaling (  p-ERK1/2, p-JNK, HSP-27, and NF-kB p-50) 
and the down-regulation of inflammatory cytokines. Whether these changes in cellular 
ROS and signaling are directly responsible for the attenuation of monocrotaline-induced 
RV hypertrophy will require further investigation.  
 
Effects of curcumin nanoparticle administration on monocrotaline-induced right 
ventricular hypertrophy in Sprague Dawley rats 
Curcumin (diferuloylmethane) is a polyphenolic compound found in turmeric that 
has been used in the ancient Indian Ayurvedic medicine for centuries to treat biliary 
disorders, anorexia, cough, diabetic wounds, liver disorders, rheumatism, and 
respiratory conditions [116]. Curcumin is a phenolic compound that has been shown to 
exhibit anti-oxidant, anti-inflammatory, anti-microbial, and anti-carcinogenic activities 
[26, 27, 177]. Recent studies have shown that curcumin administration can prevent 
cardiac hypertrophy and heart failure in a murine model of salt-induced hypertension 
[201]. In addition, curcumin has been shown to diminish the deleterious effects of 
inflammatory cytokines [204], and to inhibit pulmonary fibrosis in rats [33]. 
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Similarly, Yao and coworkers demonstrated that curcumin could inhibit the 
pressure overload left ventricular hypertrophy in rabbits and that this finding was 
associated with diminished tumor necrosis factor-alpha levels, decreased matrix 
metalloproteinase-2 expression and the  inhibition of collagen remodeling [184]. 
 
Here for the first time we observed that Cur NP administration is capable of 
preventing monocrotaline-induced PAH and RV hypertrophy in male Sprague Dawley 
rats (Chapter 3, Paper #2). Our echocardiography and histological data demonstrate 
that Cur NP administration was associated with diminished RV weight to body weight 
ratio, decreased RV anterior free wall thickness and diminished RV myocardial fibrosis. 
We also observed that Cur NP administration was associated with decreases in protein 
expression of cardiac remodeling ( β-MHC and fibronectin), decreases in oxidative 
stress associated signaling (  HSP-27, HSP-70, and  nitro-tyrosine) and the down-
regulation of inflammatory cytokines. Whether these changes in molecular signaling are 
directly responsible for the amelioration of monocrotaline-induced RV hypertrophy will 
require further investigation. 
 
SUMMARY 
 
1. Monocrotaline insult is associated with significant increases in pulmonary arterial 
pressure and right ventricular hypertrophy in the male Sprague Dawley rats. 
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2. Monocrotaline-induced right ventricular hypertrophy is associated with increases 
in indices of oxidative stress (superoxide anion, protein carbonylation) and 
protein nitrosylation. 
3. The administration of CeO2 nanoparticles appeared to attenuate monocrotaline-
induced increases in pulmonary arterial pressure along with right ventricular 
cardiomyocyte cross sectional area and fibrosis. 
4. The administration of CeO2 nanoparticles attenuated monocrotaline-induced 
increases in oxidative stress.  
5. The administration of CeO2 nanoparticles reduced monocrotaline-induced 
increases in ERK1/2, JNK, HSP-27 and NF-kB activation. 
6. CeO2 nanoparticles treated animals exhibited diminished monocrotaline 
associated apoptotic signaling. 
7. Curcumin nanoparticle administration attenuated monocrotaline-induced 
increases in right ventricular hypertrophy and fibrosis. 
8. Curcumin nanoparticle administration was associated with diminished 
monocrotaline associated increases in serum TNF-α and decreased cardiac heat 
shock protein expression.  
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Figure 4-1. Possible role of CeO2 nanoparticles in attenuation of MCT-induced RV 
hypertrophy following pulmonary arterial hypertension. 
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Figure 4-2. Possible role of Cur NP in cardiac remodeling following pulmonary 
arterial hypertension. 
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FUTURE DIRECTIONS 
 
The present study investigated the efficacy of using nanoparticles to attenuate 
the development of the cardiac hypertrophy seen following pulmonary arterial 
hypertension in the male Sprague Dawley rats. Our data suggest that the administration 
of CeO2 and curcumin nanoparticles is capable of diminishing MCT-induced increases 
in pulmonary arterial pressure and indices of right ventricular hypertrophy, myocardial 
oxidative stress, and apoptosis in male Sprague Dawley rats. Although these results are 
promising, additional studies are required to determine the exact mechanism(s) 
responsible for these findings. Future areas of study could include the following areas of 
inquiry. 
 
It is possible that the distribution and accumulation of nanoparticles in the body 
may pose deleterious effects on the health of individuals. Determination of 
CeO2/curcumin nanoparticles levels in the blood and tissues (pulmonary artery, lung, 
heart, liver and kidney) is of interest to determine whether treatment with these 
materials is potentially hazardous. Findings from the present study suggest that 
treatment with CeO2/curcumin nanoparticles is able to diminish MCT-induced increases 
in cardiac oxidative stress in male Sprague Dawley rats. Little is currently known about 
how the administration of CeO2/curcumin nanoparticles may provide cardioprotective 
effects. Previous reports suggested that CeO2 nanoparticles may act as antioxidant 
[107]. Similarly, curcumin has been suggested to exhibit antioxidant and anti-
inflammatory effects [205]. Future studies could be directed at investigating whether the 
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effect of CeO2 or curcumin nanoparticle treatment is due to increased free radical 
scavenging or due to the increased expression of antioxidant enzymes. 
 
Previous studies have shown that CeO2 nanoparticles can attenuate the effects 
of chronic inflammation by acting as free radical scavengers [15]. To directly assess this 
possibility in endothelial cells, bovine pulmonary artery endothelial cells (BPAE) cells 
could be exposed to various concentrations of H2O2 with and without CeO2 
nanoparticles in the media. Treatment effectiveness could be established with the 
measurement of 2’,7’-dichlorfluorescein-diacetate (DCFH-DA) fluorescence intensity or 
by assessing cell viability with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT)  assay. 
 
Findings from the present study suggest that CeO2/curcumin nanoparticle 
treatment may attenuate MCT-induced RV hypertrophy following pulmonary arterial 
hypertension. How CeO2/curcumin nanoparticle administration attenuated pulmonary 
arterial pressure is not clear. Future studies could explore whether nanoparticle 
administration has an effect on MCT-induced pulmonary artery fibrosis and stiffness. 
Similarly, other experiments could examine the lungs for changes in inflammatory 
markers, oxidative stress levels and cellular apoptosis. Results from such studies will no 
doubt help us to better understand the disease process and therapeutic efficiency. 
 
According to the reports from the Center for Disease Control and Prevention the 
incidence of PAH is ~4:1  higher in women than men [206]. Why more women suffer 
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from PAH than men is currently not clear. Future studies using female rats could further 
our understanding of the influence of sex on the pathophysilogy of monocrotaline-
induced pulmonary arterial hypertension and could be invaluable for helping to 
determine whether treatment with CeO2/curcumin nanoparticles is safe.  
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